| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 359 | 2025 | 657 | 53.640 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 135 | 2025 | 155 | 29.870 |
Why?
|
| Lung Diseases, Interstitial | 75 | 2024 | 129 | 12.640 |
Why?
|
| Lung | 165 | 2025 | 920 | 12.620 |
Why?
|
| Bronchodilator Agents | 73 | 2025 | 122 | 11.210 |
Why?
|
| Pulmonary Emphysema | 59 | 2024 | 99 | 8.320 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 30 | 2023 | 34 | 8.260 |
Why?
|
| Forced Expiratory Volume | 117 | 2025 | 193 | 7.620 |
Why?
|
| Disease Progression | 123 | 2025 | 1119 | 6.970 |
Why?
|
| Glycopyrrolate | 18 | 2025 | 23 | 6.710 |
Why?
|
| Pulmonary Fibrosis | 53 | 2025 | 79 | 6.690 |
Why?
|
| Humans | 839 | 2025 | 59440 | 6.680 |
Why?
|
| Double-Blind Method | 95 | 2025 | 715 | 5.710 |
Why?
|
| Middle Aged | 415 | 2025 | 16335 | 5.670 |
Why?
|
| Chlorobenzenes | 26 | 2025 | 27 | 5.610 |
Why?
|
| Tomography, X-Ray Computed | 103 | 2025 | 1512 | 5.540 |
Why?
|
| Aged | 353 | 2025 | 13426 | 5.430 |
Why?
|
| Muscarinic Antagonists | 17 | 2021 | 32 | 5.420 |
Why?
|
| Formoterol Fumarate | 18 | 2025 | 20 | 5.400 |
Why?
|
| Male | 490 | 2025 | 27775 | 5.170 |
Why?
|
| Adrenal Cortex Hormones | 44 | 2024 | 168 | 5.160 |
Why?
|
| Benzyl Alcohols | 26 | 2025 | 28 | 5.090 |
Why?
|
| Asthma | 52 | 2024 | 460 | 5.050 |
Why?
|
| Female | 500 | 2025 | 30757 | 4.920 |
Why?
|
| Severity of Illness Index | 96 | 2025 | 1482 | 4.720 |
Why?
|
| Respiratory Function Tests | 75 | 2023 | 189 | 4.530 |
Why?
|
| Androstadienes | 27 | 2025 | 39 | 4.440 |
Why?
|
| Vital Capacity | 71 | 2025 | 105 | 4.400 |
Why?
|
| Smoking | 62 | 2025 | 826 | 4.310 |
Why?
|
| Administration, Inhalation | 63 | 2025 | 145 | 4.260 |
Why?
|
| Glucocorticoids | 19 | 2022 | 180 | 3.640 |
Why?
|
| Quality of Life | 64 | 2025 | 1138 | 3.590 |
Why?
|
| Biomarkers | 69 | 2025 | 1306 | 3.540 |
Why?
|
| Budesonide | 14 | 2025 | 20 | 3.540 |
Why?
|
| Spirometry | 54 | 2025 | 104 | 3.490 |
Why?
|
| Anti-Bacterial Agents | 32 | 2024 | 735 | 3.390 |
Why?
|
| Treatment Outcome | 119 | 2025 | 5287 | 3.100 |
Why?
|
| Metered Dose Inhalers | 13 | 2022 | 16 | 3.000 |
Why?
|
| Bronchitis, Chronic | 13 | 2023 | 16 | 2.980 |
Why?
|
| Drug Therapy, Combination | 41 | 2025 | 451 | 2.890 |
Why?
|
| Pneumonectomy | 29 | 2012 | 98 | 2.860 |
Why?
|
| Precision Medicine | 12 | 2024 | 102 | 2.820 |
Why?
|
| Clinical Trials as Topic | 21 | 2024 | 440 | 2.750 |
Why?
|
| Lung Transplantation | 35 | 2024 | 67 | 2.750 |
Why?
|
| Aminopyridines | 11 | 2018 | 31 | 2.700 |
Why?
|
| Benzamides | 11 | 2018 | 63 | 2.670 |
Why?
|
| Biopsy | 42 | 2022 | 410 | 2.600 |
Why?
|
| Quinuclidines | 12 | 2025 | 21 | 2.600 |
Why?
|
| Prognosis | 71 | 2025 | 1597 | 2.490 |
Why?
|
| Dyspnea | 27 | 2023 | 116 | 2.460 |
Why?
|
| Indoles | 14 | 2025 | 106 | 2.400 |
Why?
|
| Adult | 196 | 2025 | 15695 | 2.280 |
Why?
|
| Surveys and Questionnaires | 50 | 2023 | 2517 | 2.220 |
Why?
|
| Azithromycin | 11 | 2021 | 27 | 2.220 |
Why?
|
| Cardiovascular Diseases | 24 | 2025 | 789 | 2.200 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 12 | 2025 | 13 | 2.180 |
Why?
|
| Microbiota | 14 | 2024 | 103 | 2.070 |
Why?
|
| Aged, 80 and over | 82 | 2024 | 5129 | 2.070 |
Why?
|
| Emphysema | 16 | 2024 | 34 | 2.010 |
Why?
|
| Periodicals as Topic | 6 | 2022 | 166 | 2.010 |
Why?
|
| Risk Factors | 85 | 2025 | 4990 | 1.990 |
Why?
|
| Pulmonary Medicine | 9 | 2022 | 40 | 1.950 |
Why?
|
| Hypertension, Pulmonary | 20 | 2022 | 92 | 1.900 |
Why?
|
| Randomized Controlled Trials as Topic | 24 | 2024 | 678 | 1.850 |
Why?
|
| Drug Combinations | 27 | 2022 | 147 | 1.830 |
Why?
|
| Fibroblasts | 24 | 2024 | 377 | 1.830 |
Why?
|
| Research Design | 14 | 2024 | 556 | 1.780 |
Why?
|
| Lung Diseases | 19 | 2025 | 170 | 1.780 |
Why?
|
| Cohort Studies | 61 | 2025 | 2376 | 1.740 |
Why?
|
| Lung Diseases, Obstructive | 17 | 2012 | 33 | 1.720 |
Why?
|
| United States | 77 | 2025 | 7430 | 1.700 |
Why?
|
| Mass Screening | 8 | 2023 | 651 | 1.690 |
Why?
|
| Eosinophils | 8 | 2025 | 55 | 1.660 |
Why?
|
| Respiratory Tract Infections | 8 | 2021 | 84 | 1.650 |
Why?
|
| Phenotype | 31 | 2025 | 1137 | 1.640 |
Why?
|
| Fluticasone | 11 | 2022 | 16 | 1.610 |
Why?
|
| Editorial Policies | 3 | 2022 | 52 | 1.610 |
Why?
|
| Immunosuppressive Agents | 23 | 2023 | 365 | 1.600 |
Why?
|
| Prospective Studies | 66 | 2025 | 3069 | 1.580 |
Why?
|
| Hospitalization | 31 | 2025 | 1293 | 1.580 |
Why?
|
| Smokers | 20 | 2023 | 116 | 1.560 |
Why?
|
| Bronchi | 12 | 2021 | 82 | 1.560 |
Why?
|
| Kidney Transplantation | 17 | 2015 | 314 | 1.560 |
Why?
|
| Genetic Predisposition to Disease | 26 | 2025 | 676 | 1.540 |
Why?
|
| Polymorphism, Single Nucleotide | 25 | 2024 | 439 | 1.520 |
Why?
|
| Proportional Hazards Models | 36 | 2024 | 674 | 1.510 |
Why?
|
| Predictive Value of Tests | 35 | 2021 | 1028 | 1.490 |
Why?
|
| Antibodies, Monoclonal, Humanized | 9 | 2025 | 217 | 1.480 |
Why?
|
| Diagnosis, Differential | 33 | 2024 | 933 | 1.470 |
Why?
|
| Cystic Fibrosis | 6 | 2023 | 110 | 1.470 |
Why?
|
| Mortality | 3 | 2021 | 155 | 1.450 |
Why?
|
| Scleroderma, Systemic | 7 | 2024 | 20 | 1.410 |
Why?
|
| Acetylcysteine | 6 | 2022 | 27 | 1.390 |
Why?
|
| Bacterial Infections | 9 | 2014 | 140 | 1.380 |
Why?
|
| Early Diagnosis | 8 | 2024 | 91 | 1.350 |
Why?
|
| Critical Care | 5 | 2022 | 399 | 1.320 |
Why?
|
| Exercise Tolerance | 18 | 2024 | 75 | 1.310 |
Why?
|
| Primary Health Care | 7 | 2024 | 651 | 1.310 |
Why?
|
| Anti-Infective Agents | 6 | 2024 | 143 | 1.310 |
Why?
|
| Biomedical Research | 9 | 2024 | 256 | 1.300 |
Why?
|
| Machine Learning | 4 | 2024 | 154 | 1.300 |
Why?
|
| Pyridones | 8 | 2025 | 37 | 1.290 |
Why?
|
| Idiopathic Interstitial Pneumonias | 8 | 2021 | 9 | 1.280 |
Why?
|
| Hypertension | 12 | 2022 | 570 | 1.270 |
Why?
|
| Tiotropium Bromide | 8 | 2020 | 17 | 1.270 |
Why?
|
| Alveolitis, Extrinsic Allergic | 9 | 2022 | 15 | 1.260 |
Why?
|
| Respiratory Tract Diseases | 4 | 2023 | 34 | 1.230 |
Why?
|
| Air Pollution | 6 | 2024 | 29 | 1.220 |
Why?
|
| Airway Obstruction | 10 | 2022 | 37 | 1.220 |
Why?
|
| Anti-Inflammatory Agents | 12 | 2020 | 164 | 1.210 |
Why?
|
| Risk Assessment | 29 | 2022 | 1926 | 1.200 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2019 | 202 | 1.170 |
Why?
|
| Enzyme Inhibitors | 8 | 2018 | 347 | 1.130 |
Why?
|
| Disease Management | 9 | 2021 | 220 | 1.130 |
Why?
|
| Albuterol | 7 | 2014 | 24 | 1.100 |
Why?
|
| Patient Selection | 15 | 2019 | 465 | 1.090 |
Why?
|
| Nebulizers and Vaporizers | 12 | 2022 | 36 | 1.090 |
Why?
|
| Sensitivity and Specificity | 27 | 2021 | 1097 | 1.080 |
Why?
|
| Asymptomatic Diseases | 3 | 2017 | 46 | 1.080 |
Why?
|
| Follow-Up Studies | 46 | 2025 | 2339 | 1.070 |
Why?
|
| Oxygen Inhalation Therapy | 10 | 2021 | 57 | 1.070 |
Why?
|
| Multicenter Studies as Topic | 15 | 2022 | 130 | 1.070 |
Why?
|
| Time Factors | 42 | 2024 | 3621 | 1.040 |
Why?
|
| Societies, Medical | 16 | 2025 | 338 | 1.040 |
Why?
|
| Respiratory Therapy | 4 | 2021 | 12 | 1.040 |
Why?
|
| Retrospective Studies | 60 | 2024 | 6081 | 1.040 |
Why?
|
| Blood Pressure | 15 | 2022 | 496 | 1.010 |
Why?
|
| Survival Rate | 34 | 2019 | 801 | 1.000 |
Why?
|
| Mucin-5B | 8 | 2024 | 9 | 0.980 |
Why?
|
| Air Pollutants | 5 | 2023 | 76 | 0.980 |
Why?
|
| RNA, Ribosomal, 16S | 10 | 2024 | 78 | 0.980 |
Why?
|
| Health Status | 15 | 2020 | 426 | 0.960 |
Why?
|
| Sildenafil Citrate | 5 | 2019 | 11 | 0.960 |
Why?
|
| Indians, North American | 3 | 2015 | 27 | 0.940 |
Why?
|
| Endpoint Determination | 5 | 2020 | 24 | 0.940 |
Why?
|
| Genome-Wide Association Study | 12 | 2023 | 331 | 0.910 |
Why?
|
| Patient Advocacy | 2 | 2024 | 38 | 0.910 |
Why?
|
| Pneumonia | 9 | 2023 | 282 | 0.900 |
Why?
|
| Metagenome | 4 | 2012 | 17 | 0.900 |
Why?
|
| Respiratory Mechanics | 10 | 2020 | 57 | 0.900 |
Why?
|
| Exercise Test | 19 | 2017 | 242 | 0.890 |
Why?
|
| Pneumonia, Viral | 8 | 2020 | 205 | 0.880 |
Why?
|
| Cross-Sectional Studies | 31 | 2025 | 2382 | 0.870 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2022 | 170 | 0.870 |
Why?
|
| Bronchiolitis Obliterans | 8 | 2014 | 20 | 0.860 |
Why?
|
| Eosinophilia | 3 | 2025 | 30 | 0.860 |
Why?
|
| Polymorphism, Genetic | 7 | 2020 | 185 | 0.850 |
Why?
|
| Reproducibility of Results | 18 | 2025 | 1560 | 0.850 |
Why?
|
| Albuminuria | 4 | 2021 | 29 | 0.830 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 2 | 2019 | 7 | 0.820 |
Why?
|
| Doxycycline | 3 | 2021 | 42 | 0.810 |
Why?
|
| Proteomics | 8 | 2024 | 263 | 0.810 |
Why?
|
| Indans | 2 | 2013 | 12 | 0.810 |
Why?
|
| Symptom Assessment | 6 | 2019 | 44 | 0.810 |
Why?
|
| Acute Disease | 23 | 2018 | 660 | 0.810 |
Why?
|
| Pneumonia, Bacterial | 7 | 2014 | 88 | 0.810 |
Why?
|
| Inflammation | 10 | 2024 | 1099 | 0.800 |
Why?
|
| Quinolones | 2 | 2013 | 27 | 0.800 |
Why?
|
| Sex Factors | 16 | 2017 | 935 | 0.790 |
Why?
|
| Macrolides | 6 | 2019 | 37 | 0.790 |
Why?
|
| Fibrinogen | 4 | 2021 | 31 | 0.790 |
Why?
|
| Sleep Medicine Specialty | 1 | 2022 | 3 | 0.770 |
Why?
|
| Advisory Committees | 5 | 2023 | 108 | 0.770 |
Why?
|
| Sputum | 7 | 2024 | 36 | 0.760 |
Why?
|
| Amyotrophic Lateral Sclerosis | 5 | 2021 | 480 | 0.760 |
Why?
|
| Kaplan-Meier Estimate | 15 | 2021 | 396 | 0.760 |
Why?
|
| Epithelial Cells | 7 | 2021 | 391 | 0.750 |
Why?
|
| Genotype | 19 | 2022 | 619 | 0.740 |
Why?
|
| Patient-Centered Care | 3 | 2021 | 246 | 0.740 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2019 | 47 | 0.740 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2021 | 9 | 0.740 |
Why?
|
| Coronavirus Infections | 6 | 2020 | 192 | 0.730 |
Why?
|
| DNA, Mitochondrial | 4 | 2024 | 76 | 0.720 |
Why?
|
| Practice Guidelines as Topic | 15 | 2021 | 706 | 0.720 |
Why?
|
| Attitude to Health | 3 | 2014 | 279 | 0.720 |
Why?
|
| Case-Control Studies | 22 | 2023 | 1054 | 0.710 |
Why?
|
| Tephritidae | 1 | 2020 | 1 | 0.710 |
Why?
|
| Asteraceae | 1 | 2020 | 2 | 0.710 |
Why?
|
| Wasps | 1 | 2020 | 2 | 0.710 |
Why?
|
| Clinical Trials, Phase III as Topic | 7 | 2022 | 40 | 0.710 |
Why?
|
| Algorithms | 11 | 2019 | 978 | 0.710 |
Why?
|
| Age Factors | 22 | 2022 | 1505 | 0.700 |
Why?
|
| Telomere | 7 | 2024 | 50 | 0.700 |
Why?
|
| Sleep Apnea, Obstructive | 4 | 2022 | 54 | 0.700 |
Why?
|
| Incidence | 23 | 2021 | 1239 | 0.690 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 154 | 0.690 |
Why?
|
| Evidence-Based Medicine | 8 | 2021 | 443 | 0.690 |
Why?
|
| Transcriptome | 5 | 2022 | 340 | 0.690 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 5 | 2024 | 328 | 0.690 |
Why?
|
| Respiratory Mucosa | 4 | 2021 | 54 | 0.690 |
Why?
|
| Cholinergic Antagonists | 4 | 2019 | 33 | 0.690 |
Why?
|
| Age of Onset | 3 | 2018 | 170 | 0.680 |
Why?
|
| Drug Administration Schedule | 12 | 2018 | 284 | 0.680 |
Why?
|
| Immunoglobulin G | 7 | 2025 | 446 | 0.680 |
Why?
|
| Dose-Response Relationship, Drug | 16 | 2025 | 805 | 0.680 |
Why?
|
| Sepsis | 2 | 2023 | 274 | 0.680 |
Why?
|
| Prednisone | 7 | 2019 | 85 | 0.670 |
Why?
|
| ROC Curve | 12 | 2022 | 268 | 0.670 |
Why?
|
| Benzoxazines | 2 | 2020 | 10 | 0.670 |
Why?
|
| Chronic Disease | 17 | 2025 | 717 | 0.670 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2024 | 19 | 0.670 |
Why?
|
| Pulse Wave Analysis | 5 | 2020 | 13 | 0.670 |
Why?
|
| Survival Analysis | 20 | 2024 | 554 | 0.670 |
Why?
|
| Respiratory System | 6 | 2020 | 45 | 0.670 |
Why?
|
| Cyclopropanes | 11 | 2018 | 50 | 0.660 |
Why?
|
| Global Health | 9 | 2021 | 167 | 0.660 |
Why?
|
| Motor Neurons | 4 | 2021 | 203 | 0.650 |
Why?
|
| Carbon Monoxide | 9 | 2019 | 61 | 0.640 |
Why?
|
| Pulmonary Artery | 5 | 2024 | 88 | 0.640 |
Why?
|
| Uteroglobin | 2 | 2019 | 7 | 0.630 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2020 | 119 | 0.630 |
Why?
|
| Social Behavior | 1 | 2020 | 87 | 0.630 |
Why?
|
| Telomerase | 3 | 2024 | 31 | 0.630 |
Why?
|
| Alternative Splicing | 2 | 2016 | 122 | 0.620 |
Why?
|
| Longitudinal Studies | 21 | 2025 | 1188 | 0.620 |
Why?
|
| Respiratory Insufficiency | 6 | 2022 | 148 | 0.620 |
Why?
|
| Betacoronavirus | 7 | 2021 | 166 | 0.610 |
Why?
|
| Kidney Failure, Chronic | 5 | 2010 | 206 | 0.600 |
Why?
|
| Antacids | 2 | 2022 | 12 | 0.600 |
Why?
|
| Cyclophosphamide | 4 | 2016 | 75 | 0.590 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 2 | 2019 | 5 | 0.580 |
Why?
|
| Hypoxia | 3 | 2021 | 112 | 0.580 |
Why?
|
| Respiratory Muscles | 11 | 2014 | 15 | 0.580 |
Why?
|
| Bronchitis | 5 | 2005 | 27 | 0.570 |
Why?
|
| Prevalence | 16 | 2024 | 1257 | 0.560 |
Why?
|
| DNA, Bacterial | 5 | 2014 | 259 | 0.560 |
Why?
|
| Community-Acquired Infections | 5 | 2004 | 92 | 0.550 |
Why?
|
| Adolescent | 40 | 2024 | 5844 | 0.550 |
Why?
|
| Graft Rejection | 12 | 2014 | 289 | 0.550 |
Why?
|
| Child | 37 | 2023 | 4194 | 0.540 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2016 | 2 | 0.540 |
Why?
|
| Bronchoalveolar Lavage Fluid | 13 | 2021 | 102 | 0.540 |
Why?
|
| DNA | 5 | 2021 | 805 | 0.540 |
Why?
|
| Osteopontin | 1 | 2016 | 22 | 0.540 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2016 | 10 | 0.540 |
Why?
|
| Bronchoscopy | 11 | 2022 | 86 | 0.530 |
Why?
|
| Drug Discovery | 1 | 2017 | 89 | 0.530 |
Why?
|
| Depression | 6 | 2022 | 829 | 0.530 |
Why?
|
| Peer Review, Research | 3 | 2022 | 46 | 0.530 |
Why?
|
| IgG Deficiency | 3 | 2025 | 4 | 0.530 |
Why?
|
| MicroRNAs | 4 | 2021 | 618 | 0.530 |
Why?
|
| Scopolamine Derivatives | 3 | 2013 | 13 | 0.530 |
Why?
|
| Cause of Death | 7 | 2021 | 210 | 0.520 |
Why?
|
| Toll-Like Receptor 9 | 4 | 2012 | 202 | 0.520 |
Why?
|
| Health Behavior | 2 | 2017 | 452 | 0.520 |
Why?
|
| Patients | 3 | 2023 | 103 | 0.510 |
Why?
|
| Glomerular Filtration Rate | 7 | 2011 | 101 | 0.500 |
Why?
|
| Logistic Models | 16 | 2021 | 1235 | 0.500 |
Why?
|
| Gene Expression Profiling | 8 | 2024 | 719 | 0.500 |
Why?
|
| Multivariate Analysis | 17 | 2019 | 903 | 0.500 |
Why?
|
| Environmental Exposure | 6 | 2024 | 208 | 0.500 |
Why?
|
| Patient Outcome Assessment | 4 | 2021 | 52 | 0.490 |
Why?
|
| Immunoglobulin E | 7 | 2020 | 86 | 0.490 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 3 | 2009 | 14 | 0.490 |
Why?
|
| Oxygen | 10 | 2018 | 313 | 0.490 |
Why?
|
| Young Adult | 24 | 2024 | 4273 | 0.490 |
Why?
|
| Health Status Disparities | 3 | 2021 | 137 | 0.490 |
Why?
|
| Cell Survival | 3 | 2016 | 559 | 0.480 |
Why?
|
| Pulmonary Diffusing Capacity | 12 | 2019 | 17 | 0.480 |
Why?
|
| Genetic Markers | 7 | 2022 | 116 | 0.480 |
Why?
|
| Tissue Donors | 10 | 2014 | 143 | 0.480 |
Why?
|
| Protein Transport | 1 | 2016 | 399 | 0.480 |
Why?
|
| Cigarette Smoking | 3 | 2023 | 53 | 0.470 |
Why?
|
| Survivors | 2 | 2015 | 150 | 0.470 |
Why?
|
| Walking | 5 | 2013 | 228 | 0.470 |
Why?
|
| Azathioprine | 3 | 2019 | 27 | 0.460 |
Why?
|
| Heart Diseases | 3 | 2018 | 206 | 0.460 |
Why?
|
| Regression Analysis | 16 | 2019 | 487 | 0.460 |
Why?
|
| Radiography, Thoracic | 8 | 2020 | 111 | 0.450 |
Why?
|
| Gene Expression | 10 | 2021 | 810 | 0.450 |
Why?
|
| Genomics | 6 | 2024 | 319 | 0.450 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2015 | 62 | 0.450 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2019 | 238 | 0.450 |
Why?
|
| Erythropoietin | 2 | 2012 | 35 | 0.440 |
Why?
|
| Cultural Characteristics | 1 | 2014 | 35 | 0.440 |
Why?
|
| Leukocyte Count | 8 | 2024 | 97 | 0.440 |
Why?
|
| Congresses as Topic | 1 | 2014 | 72 | 0.430 |
Why?
|
| Particulate Matter | 5 | 2024 | 52 | 0.430 |
Why?
|
| Recovery of Function | 5 | 2020 | 271 | 0.430 |
Why?
|
| Dry Powder Inhalers | 3 | 2020 | 3 | 0.420 |
Why?
|
| Matrix Metalloproteinase 9 | 3 | 2021 | 59 | 0.420 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2013 | 9 | 0.420 |
Why?
|
| Pulmonary Wedge Pressure | 5 | 2021 | 26 | 0.420 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2023 | 648 | 0.420 |
Why?
|
| Ozone | 3 | 2024 | 14 | 0.420 |
Why?
|
| Academic Medical Centers | 2 | 2023 | 310 | 0.420 |
Why?
|
| Vascular Resistance | 4 | 2013 | 48 | 0.420 |
Why?
|
| Referral and Consultation | 7 | 2024 | 406 | 0.410 |
Why?
|
| Primary Prevention | 1 | 2014 | 134 | 0.410 |
Why?
|
| Respiratory System Agents | 4 | 2020 | 6 | 0.400 |
Why?
|
| Biological Products | 2 | 2024 | 90 | 0.400 |
Why?
|
| Animals | 42 | 2021 | 19661 | 0.400 |
Why?
|
| Myofibroblasts | 1 | 2012 | 15 | 0.400 |
Why?
|
| Albumins | 1 | 2012 | 34 | 0.400 |
Why?
|
| International Cooperation | 7 | 2017 | 84 | 0.390 |
Why?
|
| Lipopolysaccharide Receptors | 3 | 2003 | 143 | 0.390 |
Why?
|
| Gastroesophageal Reflux | 4 | 2018 | 82 | 0.390 |
Why?
|
| Lymph Nodes | 3 | 2006 | 215 | 0.390 |
Why?
|
| Comorbidity | 12 | 2022 | 1078 | 0.390 |
Why?
|
| Adrenergic beta-Agonists | 4 | 2020 | 31 | 0.390 |
Why?
|
| Antibodies, Monoclonal | 8 | 2022 | 836 | 0.380 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2016 | 17 | 0.380 |
Why?
|
| Pandemics | 8 | 2024 | 617 | 0.380 |
Why?
|
| Cough | 3 | 2023 | 183 | 0.380 |
Why?
|
| Sympathomimetics | 1 | 2011 | 5 | 0.370 |
Why?
|
| Sequence Analysis, RNA | 4 | 2022 | 159 | 0.370 |
Why?
|
| Antiviral Agents | 2 | 2020 | 313 | 0.370 |
Why?
|
| Patient Admission | 2 | 2018 | 184 | 0.370 |
Why?
|
| alpha 1-Antitrypsin | 3 | 2022 | 87 | 0.370 |
Why?
|
| Delayed Graft Function | 2 | 2010 | 4 | 0.370 |
Why?
|
| Culture | 1 | 2011 | 73 | 0.370 |
Why?
|
| Kidney | 9 | 2022 | 414 | 0.370 |
Why?
|
| Dexamethasone | 2 | 2024 | 201 | 0.370 |
Why?
|
| Body Mass Index | 10 | 2022 | 831 | 0.370 |
Why?
|
| Pyrimidines | 4 | 2021 | 131 | 0.370 |
Why?
|
| Lung Neoplasms | 9 | 2020 | 584 | 0.370 |
Why?
|
| Ofloxacin | 3 | 2005 | 8 | 0.370 |
Why?
|
| Forecasting | 5 | 2023 | 221 | 0.360 |
Why?
|
| Blood Proteins | 4 | 2024 | 75 | 0.360 |
Why?
|
| Levofloxacin | 3 | 2005 | 12 | 0.360 |
Why?
|
| Pyrazoles | 3 | 2021 | 65 | 0.360 |
Why?
|
| Postoperative Complications | 11 | 2017 | 1204 | 0.360 |
Why?
|
| Self Care | 2 | 2011 | 207 | 0.360 |
Why?
|
| Virus Diseases | 4 | 2007 | 114 | 0.360 |
Why?
|
| Gene Expression Regulation | 8 | 2024 | 1553 | 0.360 |
Why?
|
| Child, Preschool | 19 | 2019 | 1794 | 0.360 |
Why?
|
| Patient Acuity | 2 | 2021 | 22 | 0.350 |
Why?
|
| Analysis of Variance | 11 | 2017 | 591 | 0.350 |
Why?
|
| Arteries | 1 | 2011 | 76 | 0.350 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 263 | 0.350 |
Why?
|
| Cost-Benefit Analysis | 4 | 2024 | 299 | 0.350 |
Why?
|
| Aging | 3 | 2024 | 710 | 0.350 |
Why?
|
| Mucus | 5 | 2022 | 15 | 0.350 |
Why?
|
| Treatment Failure | 7 | 2019 | 185 | 0.350 |
Why?
|
| Respiration, Artificial | 6 | 2022 | 292 | 0.350 |
Why?
|
| Fluticasone-Salmeterol Drug Combination | 3 | 2016 | 3 | 0.340 |
Why?
|
| Obesity | 8 | 2022 | 1166 | 0.340 |
Why?
|
| Linear Models | 8 | 2024 | 403 | 0.340 |
Why?
|
| United Kingdom | 2 | 2024 | 66 | 0.340 |
Why?
|
| Administration, Oral | 8 | 2025 | 355 | 0.340 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2012 | 725 | 0.340 |
Why?
|
| Arm | 5 | 1999 | 42 | 0.340 |
Why?
|
| Panic Disorder | 1 | 2010 | 31 | 0.340 |
Why?
|
| Patient Preference | 2 | 2020 | 78 | 0.330 |
Why?
|
| Streptococcus pneumoniae | 5 | 2009 | 63 | 0.330 |
Why?
|
| Oxygen Consumption | 7 | 2011 | 207 | 0.330 |
Why?
|
| Adaptation, Psychological | 1 | 2011 | 259 | 0.330 |
Why?
|
| Granulocytes | 3 | 2024 | 70 | 0.320 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2018 | 651 | 0.320 |
Why?
|
| Receptors, Mineralocorticoid | 1 | 2009 | 4 | 0.320 |
Why?
|
| Piperazines | 3 | 2013 | 74 | 0.320 |
Why?
|
| Mycophenolic Acid | 5 | 2023 | 66 | 0.320 |
Why?
|
| France | 2 | 2024 | 13 | 0.320 |
Why?
|
| Physicians | 3 | 2023 | 442 | 0.320 |
Why?
|
| Exosomes | 2 | 2021 | 44 | 0.320 |
Why?
|
| Biopsy, Needle | 7 | 2006 | 134 | 0.320 |
Why?
|
| Metabolic Diseases | 3 | 2016 | 54 | 0.310 |
Why?
|
| Genetic Variation | 4 | 2025 | 357 | 0.310 |
Why?
|
| Bronchiolitis | 3 | 2008 | 17 | 0.310 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2015 | 621 | 0.310 |
Why?
|
| Risk | 9 | 2019 | 364 | 0.300 |
Why?
|
| Mutation | 8 | 2023 | 2458 | 0.300 |
Why?
|
| Oximetry | 3 | 2025 | 48 | 0.300 |
Why?
|
| Staphylococcus | 2 | 2014 | 17 | 0.300 |
Why?
|
| Internationality | 6 | 2019 | 43 | 0.300 |
Why?
|
| Mice | 25 | 2021 | 10300 | 0.300 |
Why?
|
| DNA Methylation | 4 | 2021 | 272 | 0.300 |
Why?
|
| Tobacco Products | 3 | 2023 | 71 | 0.300 |
Why?
|
| Antigens | 2 | 2021 | 146 | 0.300 |
Why?
|
| Pulmonary Gas Exchange | 3 | 2020 | 43 | 0.290 |
Why?
|
| Alleles | 5 | 2018 | 411 | 0.290 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 148 | 0.290 |
Why?
|
| Neoplasms | 4 | 2015 | 1232 | 0.290 |
Why?
|
| Flow Cytometry | 10 | 2020 | 645 | 0.280 |
Why?
|
| Allergens | 3 | 2022 | 50 | 0.280 |
Why?
|
| Ambulatory Care | 2 | 2012 | 305 | 0.280 |
Why?
|
| Induced Pluripotent Stem Cells | 4 | 2021 | 139 | 0.280 |
Why?
|
| North America | 4 | 2023 | 105 | 0.280 |
Why?
|
| Quercetin | 3 | 2020 | 26 | 0.280 |
Why?
|
| Anxiety | 3 | 2021 | 387 | 0.280 |
Why?
|
| Antioxidants | 4 | 2020 | 241 | 0.280 |
Why?
|
| Community Medicine | 1 | 2007 | 6 | 0.280 |
Why?
|
| Mucin 5AC | 3 | 2022 | 9 | 0.270 |
Why?
|
| Carotid Arteries | 3 | 2016 | 62 | 0.270 |
Why?
|
| Blood Donors | 2 | 2024 | 22 | 0.270 |
Why?
|
| Sarcoidosis, Pulmonary | 4 | 2015 | 14 | 0.270 |
Why?
|
| Nitric Oxide | 4 | 2021 | 146 | 0.270 |
Why?
|
| Calcitonin | 1 | 2007 | 17 | 0.270 |
Why?
|
| Myocardial Infarction | 4 | 2025 | 863 | 0.270 |
Why?
|
| Respiration | 7 | 2022 | 88 | 0.270 |
Why?
|
| Cells, Cultured | 15 | 2021 | 2095 | 0.270 |
Why?
|
| Pneumothorax | 3 | 2017 | 49 | 0.270 |
Why?
|
| Epigenesis, Genetic | 4 | 2017 | 358 | 0.260 |
Why?
|
| Lung Injury | 3 | 2019 | 32 | 0.260 |
Why?
|
| Protein Precursors | 1 | 2007 | 75 | 0.260 |
Why?
|
| Needs Assessment | 3 | 2022 | 187 | 0.260 |
Why?
|
| Growth Differentiation Factor 15 | 2 | 2017 | 4 | 0.260 |
Why?
|
| Forced Expiratory Flow Rates | 2 | 2020 | 3 | 0.260 |
Why?
|
| Femoral Artery | 3 | 2016 | 103 | 0.260 |
Why?
|
| Cost of Illness | 3 | 2018 | 156 | 0.260 |
Why?
|
| Radiography | 8 | 2008 | 517 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2012 | 635 | 0.260 |
Why?
|
| Circadian Rhythm | 1 | 2010 | 373 | 0.260 |
Why?
|
| Bacteria | 3 | 2021 | 278 | 0.260 |
Why?
|
| Fatigue | 3 | 2023 | 103 | 0.260 |
Why?
|
| Patient Education as Topic | 2 | 2009 | 453 | 0.260 |
Why?
|
| Graft Survival | 10 | 2010 | 290 | 0.260 |
Why?
|
| Diagnostic Techniques, Respiratory System | 2 | 2017 | 2 | 0.260 |
Why?
|
| Smoking Cessation | 2 | 2011 | 541 | 0.260 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2023 | 74 | 0.250 |
Why?
|
| Respiration Disorders | 3 | 2021 | 23 | 0.250 |
Why?
|
| Anemia | 3 | 2018 | 119 | 0.250 |
Why?
|
| DNA-Binding Proteins | 4 | 2021 | 1151 | 0.250 |
Why?
|
| Antihypertensive Agents | 6 | 2019 | 163 | 0.250 |
Why?
|
| Early Detection of Cancer | 3 | 2020 | 267 | 0.250 |
Why?
|
| Respiratory Paralysis | 2 | 1999 | 4 | 0.250 |
Why?
|
| Pulmonary Alveoli | 4 | 2019 | 44 | 0.240 |
Why?
|
| Walk Test | 3 | 2021 | 7 | 0.240 |
Why?
|
| Interleukin-5 | 1 | 2025 | 40 | 0.240 |
Why?
|
| Palliative Care | 4 | 2013 | 214 | 0.240 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2025 | 3 | 0.240 |
Why?
|
| Cytokines | 7 | 2014 | 912 | 0.240 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 250 | 0.240 |
Why?
|
| Respiratory Hypersensitivity | 2 | 2008 | 12 | 0.240 |
Why?
|
| Patient Readmission | 2 | 2019 | 421 | 0.240 |
Why?
|
| Filgrastim | 1 | 2024 | 6 | 0.240 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2024 | 14 | 0.240 |
Why?
|
| Fibrosis | 5 | 2020 | 153 | 0.240 |
Why?
|
| Coronary Artery Disease | 2 | 2018 | 274 | 0.230 |
Why?
|
| Lung Volume Measurements | 7 | 2022 | 19 | 0.230 |
Why?
|
| Oxidative Stress | 6 | 2020 | 279 | 0.230 |
Why?
|
| Altitude | 1 | 2024 | 14 | 0.230 |
Why?
|
| Polymerase Chain Reaction | 9 | 2014 | 495 | 0.230 |
Why?
|
| Phosphodiesterase Inhibitors | 3 | 2009 | 27 | 0.230 |
Why?
|
| Liver Cirrhosis | 3 | 2017 | 163 | 0.230 |
Why?
|
| Kidney Diseases | 3 | 2022 | 170 | 0.230 |
Why?
|
| Specimen Handling | 2 | 2015 | 61 | 0.230 |
Why?
|
| Women's Health | 1 | 2007 | 360 | 0.230 |
Why?
|
| Telomere Shortening | 1 | 2024 | 8 | 0.230 |
Why?
|
| Phenylpropionates | 2 | 2015 | 10 | 0.230 |
Why?
|
| Pyridazines | 2 | 2015 | 8 | 0.230 |
Why?
|
| Electrocardiography | 4 | 2025 | 524 | 0.230 |
Why?
|
| Italy | 1 | 2024 | 63 | 0.230 |
Why?
|
| Interleukin-13 | 5 | 2014 | 37 | 0.230 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 3 | 2016 | 36 | 0.230 |
Why?
|
| Transforming Growth Factor beta | 7 | 2018 | 170 | 0.230 |
Why?
|
| Heterozygote | 2 | 2022 | 162 | 0.230 |
Why?
|
| Hypersensitivity, Immediate | 2 | 2020 | 9 | 0.230 |
Why?
|
| Lakes | 1 | 2024 | 2 | 0.230 |
Why?
|
| Journal Impact Factor | 2 | 2021 | 17 | 0.220 |
Why?
|
| Europe | 9 | 2023 | 182 | 0.220 |
Why?
|
| Trachea | 3 | 2018 | 91 | 0.220 |
Why?
|
| Peak Expiratory Flow Rate | 4 | 2017 | 10 | 0.220 |
Why?
|
| Salmeterol Xinafoate | 4 | 2019 | 7 | 0.220 |
Why?
|
| Health Surveys | 2 | 2023 | 298 | 0.220 |
Why?
|
| Heart Ventricles | 2 | 2013 | 253 | 0.220 |
Why?
|
| Health Status Indicators | 3 | 2018 | 93 | 0.220 |
Why?
|
| Antibodies | 2 | 2015 | 179 | 0.220 |
Why?
|
| Maintenance Chemotherapy | 2 | 2020 | 14 | 0.220 |
Why?
|
| Ischemic Attack, Transient | 2 | 2022 | 90 | 0.220 |
Why?
|
| Interleukin-17 | 2 | 2018 | 88 | 0.220 |
Why?
|
| Immunohistochemistry | 10 | 2012 | 851 | 0.220 |
Why?
|
| Cell Differentiation | 7 | 2013 | 1304 | 0.220 |
Why?
|
| Bronchioles | 2 | 2023 | 5 | 0.220 |
Why?
|
| Home Care Services | 1 | 2025 | 97 | 0.220 |
Why?
|
| Seasons | 1 | 2024 | 123 | 0.220 |
Why?
|
| Recombinant Proteins | 6 | 2012 | 691 | 0.220 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2022 | 322 | 0.220 |
Why?
|
| Sinusitis | 1 | 2004 | 28 | 0.220 |
Why?
|
| Symptom Flare Up | 2 | 2020 | 13 | 0.220 |
Why?
|
| Heart Rate | 4 | 2021 | 307 | 0.220 |
Why?
|
| Tuberculosis, Pulmonary | 3 | 2017 | 108 | 0.220 |
Why?
|
| Transplantation, Homologous | 8 | 2012 | 244 | 0.220 |
Why?
|
| Disease Models, Animal | 10 | 2021 | 2051 | 0.220 |
Why?
|
| Air Pollution, Indoor | 1 | 2023 | 35 | 0.220 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 330 | 0.220 |
Why?
|
| Pseudomonas Infections | 1 | 2023 | 51 | 0.210 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2021 | 23 | 0.210 |
Why?
|
| Organizational Objectives | 2 | 2021 | 57 | 0.210 |
Why?
|
| Sulfones | 3 | 2013 | 36 | 0.210 |
Why?
|
| Matrix Metalloproteinase 12 | 2 | 2013 | 3 | 0.210 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2024 | 111 | 0.210 |
Why?
|
| Data Accuracy | 1 | 2023 | 28 | 0.210 |
Why?
|
| Collagen Diseases | 1 | 2003 | 4 | 0.210 |
Why?
|
| Chemokines, CC | 4 | 2007 | 30 | 0.210 |
Why?
|
| RNA, Messenger | 11 | 2016 | 1469 | 0.210 |
Why?
|
| Molecular Targeted Therapy | 3 | 2014 | 121 | 0.210 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2013 | 446 | 0.210 |
Why?
|
| Cardiologists | 1 | 2023 | 26 | 0.210 |
Why?
|
| Pharmacogenetics | 3 | 2022 | 23 | 0.210 |
Why?
|
| Elastin | 2 | 2013 | 10 | 0.210 |
Why?
|
| Drug Approval | 2 | 2021 | 25 | 0.210 |
Why?
|
| Bone Marrow Transplantation | 3 | 1999 | 138 | 0.210 |
Why?
|
| Receptors, Chemokine | 4 | 2007 | 37 | 0.210 |
Why?
|
| Common Cold | 2 | 2021 | 9 | 0.210 |
Why?
|
| Michigan | 5 | 2021 | 41 | 0.210 |
Why?
|
| Morbidity | 5 | 2023 | 113 | 0.200 |
Why?
|
| Disease-Free Survival | 7 | 2017 | 228 | 0.200 |
Why?
|
| Patient Satisfaction | 3 | 2021 | 415 | 0.200 |
Why?
|
| Food Hypersensitivity | 1 | 2022 | 17 | 0.200 |
Why?
|
| Penicillin Resistance | 2 | 2001 | 11 | 0.200 |
Why?
|
| Marijuana Smoking | 1 | 2022 | 17 | 0.200 |
Why?
|
| Environmental Pollutants | 1 | 2023 | 91 | 0.200 |
Why?
|
| Enzyme Activators | 2 | 2019 | 4 | 0.200 |
Why?
|
| Endothelial Cells | 2 | 2021 | 173 | 0.200 |
Why?
|
| Pneumococcal Vaccines | 3 | 2012 | 19 | 0.200 |
Why?
|
| Anaphylaxis | 1 | 2022 | 40 | 0.200 |
Why?
|
| Diaphragm | 5 | 2001 | 21 | 0.200 |
Why?
|
| History, 21st Century | 3 | 2018 | 162 | 0.200 |
Why?
|
| Rhinovirus | 2 | 2013 | 4 | 0.200 |
Why?
|
| Weight Gain | 2 | 2022 | 163 | 0.200 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2002 | 29 | 0.190 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2022 | 30 | 0.190 |
Why?
|
| Diagnostic Errors | 1 | 2023 | 94 | 0.190 |
Why?
|
| Killer Cells, Natural | 2 | 2021 | 218 | 0.190 |
Why?
|
| Leukocyte Transfusion | 2 | 2012 | 16 | 0.190 |
Why?
|
| History, 20th Century | 3 | 2018 | 224 | 0.190 |
Why?
|
| Gender Identity | 2 | 2020 | 62 | 0.190 |
Why?
|
| Lung Diseases, Fungal | 2 | 2001 | 33 | 0.190 |
Why?
|
| Cell Cycle Proteins | 1 | 2024 | 385 | 0.190 |
Why?
|
| Monocytes | 3 | 2012 | 345 | 0.190 |
Why?
|
| Spain | 5 | 2018 | 32 | 0.190 |
Why?
|
| Exercise | 5 | 2016 | 883 | 0.190 |
Why?
|
| Wakefulness | 1 | 2022 | 42 | 0.190 |
Why?
|
| Penicillins | 1 | 2001 | 29 | 0.190 |
Why?
|
| Mitochondrial Myopathies | 1 | 2001 | 4 | 0.190 |
Why?
|
| Transforming Growth Factor beta1 | 6 | 2021 | 53 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 11 | 0.190 |
Why?
|
| Carrier Proteins | 2 | 2012 | 697 | 0.190 |
Why?
|
| Renal Dialysis | 4 | 2010 | 189 | 0.190 |
Why?
|
| Social Segregation | 1 | 2021 | 10 | 0.190 |
Why?
|
| Linkage Disequilibrium | 6 | 2013 | 46 | 0.190 |
Why?
|
| Arterial Pressure | 3 | 2016 | 22 | 0.190 |
Why?
|
| Avoidance Learning | 1 | 2021 | 23 | 0.190 |
Why?
|
| Sirolimus | 3 | 2015 | 88 | 0.190 |
Why?
|
| Computational Biology | 3 | 2024 | 333 | 0.190 |
Why?
|
| NADH Dehydrogenase | 1 | 2021 | 4 | 0.190 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2002 | 53 | 0.190 |
Why?
|
| Sleep Wake Disorders | 1 | 2022 | 65 | 0.190 |
Why?
|
| Pulmonary Ventilation | 3 | 2009 | 37 | 0.190 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2018 | 147 | 0.180 |
Why?
|
| Coronavirus OC43, Human | 1 | 2021 | 3 | 0.180 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2021 | 16 | 0.180 |
Why?
|
| Convalescence | 1 | 2021 | 18 | 0.180 |
Why?
|
| Leukocytes | 5 | 2023 | 97 | 0.180 |
Why?
|
| S-Nitrosothiols | 1 | 2021 | 3 | 0.180 |
Why?
|
| Child Health | 1 | 2021 | 28 | 0.180 |
Why?
|
| Immunity | 2 | 2007 | 101 | 0.180 |
Why?
|
| Echocardiography, Doppler | 2 | 1999 | 131 | 0.180 |
Why?
|
| Multiple Organ Failure | 1 | 2021 | 43 | 0.180 |
Why?
|
| Nursing Research | 1 | 2021 | 41 | 0.180 |
Why?
|
| Population Surveillance | 2 | 2019 | 195 | 0.180 |
Why?
|
| Vascular Diseases | 2 | 2013 | 75 | 0.180 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2021 | 19 | 0.180 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 208 | 0.180 |
Why?
|
| Network Meta-Analysis | 1 | 2020 | 12 | 0.180 |
Why?
|
| Fumarates | 1 | 2021 | 10 | 0.180 |
Why?
|
| Budesonide, Formoterol Fumarate Drug Combination | 2 | 2021 | 2 | 0.180 |
Why?
|
| Goblet Cells | 1 | 2020 | 8 | 0.180 |
Why?
|
| Muscle, Smooth | 4 | 2015 | 137 | 0.180 |
Why?
|
| Syndrome | 4 | 2022 | 170 | 0.180 |
Why?
|
| Gene Frequency | 5 | 2018 | 118 | 0.180 |
Why?
|
| Argentina | 1 | 2020 | 7 | 0.180 |
Why?
|
| Neovascularization, Physiologic | 2 | 2021 | 101 | 0.180 |
Why?
|
| Drug Interactions | 2 | 2019 | 115 | 0.180 |
Why?
|
| Recurrence | 7 | 2013 | 603 | 0.180 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2007 | 32 | 0.180 |
Why?
|
| Clinical Deterioration | 1 | 2020 | 3 | 0.170 |
Why?
|
| Iron-Binding Proteins | 1 | 2020 | 8 | 0.170 |
Why?
|
| Urban Population | 1 | 2021 | 180 | 0.170 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 65 | 0.170 |
Why?
|
| Anniversaries and Special Events | 2 | 2017 | 14 | 0.170 |
Why?
|
| Extracellular Matrix | 4 | 2016 | 132 | 0.170 |
Why?
|
| Agammaglobulinemia | 1 | 2020 | 8 | 0.170 |
Why?
|
| Reverse Genetics | 1 | 2020 | 10 | 0.170 |
Why?
|
| Status Asthmaticus | 1 | 2020 | 6 | 0.170 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 95 | 0.170 |
Why?
|
| Phosphoproteins | 2 | 2011 | 212 | 0.170 |
Why?
|
| Vasodilator Agents | 4 | 2013 | 63 | 0.170 |
Why?
|
| Host-Parasite Interactions | 1 | 2020 | 55 | 0.170 |
Why?
|
| Life Style | 3 | 2019 | 299 | 0.170 |
Why?
|
| Parenchymal Tissue | 2 | 2017 | 5 | 0.170 |
Why?
|
| Antibodies, Neutralizing | 3 | 2020 | 178 | 0.170 |
Why?
|
| Vascular Stiffness | 1 | 2020 | 13 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2018 | 126 | 0.170 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2020 | 6 | 0.170 |
Why?
|
| Peptide Fragments | 3 | 2018 | 401 | 0.170 |
Why?
|
| Phosphodiesterase 3 Inhibitors | 1 | 2020 | 1 | 0.170 |
Why?
|
| Consensus | 5 | 2023 | 193 | 0.170 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2016 | 217 | 0.170 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 27 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2021 | 529 | 0.170 |
Why?
|
| Alanine | 1 | 2020 | 49 | 0.170 |
Why?
|
| Pyrimidinones | 1 | 2020 | 15 | 0.170 |
Why?
|
| Cholesterol Side-Chain Cleavage Enzyme | 1 | 2000 | 4 | 0.170 |
Why?
|
| Corpus Luteum | 1 | 2000 | 8 | 0.170 |
Why?
|
| Bottle Feeding | 1 | 2000 | 4 | 0.170 |
Why?
|
| Occupational Diseases | 3 | 2015 | 263 | 0.170 |
Why?
|
| Down-Regulation | 3 | 2021 | 307 | 0.170 |
Why?
|
| Maternal Welfare | 1 | 2000 | 15 | 0.170 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2019 | 4 | 0.170 |
Why?
|
| Interleukin-8 | 3 | 2017 | 87 | 0.170 |
Why?
|
| Isoquinolines | 1 | 2020 | 32 | 0.170 |
Why?
|
| Drug Resistance | 2 | 2018 | 95 | 0.170 |
Why?
|
| Metoprolol | 1 | 2019 | 11 | 0.170 |
Why?
|
| Promoter Regions, Genetic | 5 | 2018 | 652 | 0.170 |
Why?
|
| Nuclear Proteins | 1 | 2024 | 750 | 0.160 |
Why?
|
| Macrophages, Alveolar | 2 | 2013 | 61 | 0.160 |
Why?
|
| Medical Records | 2 | 2018 | 133 | 0.160 |
Why?
|
| Iron | 1 | 2020 | 136 | 0.160 |
Why?
|
| X-Ray Microtomography | 1 | 2019 | 24 | 0.160 |
Why?
|
| Motor Activity | 2 | 2013 | 333 | 0.160 |
Why?
|
| Haplotypes | 5 | 2009 | 115 | 0.160 |
Why?
|
| Statistics, Nonparametric | 4 | 2014 | 209 | 0.160 |
Why?
|
| Gene Regulatory Networks | 2 | 2021 | 147 | 0.160 |
Why?
|
| Creatinine | 4 | 2010 | 128 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2019 | 693 | 0.160 |
Why?
|
| Endocrine System Diseases | 1 | 1999 | 10 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 11 | 2021 | 3236 | 0.160 |
Why?
|
| Total Lung Capacity | 5 | 2011 | 11 | 0.160 |
Why?
|
| Rotator Cuff | 1 | 2019 | 10 | 0.160 |
Why?
|
| Primary Graft Dysfunction | 2 | 2009 | 4 | 0.160 |
Why?
|
| Rotator Cuff Injuries | 1 | 2019 | 8 | 0.160 |
Why?
|
| Health Services Accessibility | 4 | 2024 | 527 | 0.160 |
Why?
|
| Standard of Care | 1 | 2019 | 27 | 0.160 |
Why?
|
| Progesterone | 2 | 2000 | 158 | 0.160 |
Why?
|
| Bursitis | 1 | 2019 | 13 | 0.160 |
Why?
|
| Shoulder Joint | 1 | 2019 | 24 | 0.160 |
Why?
|
| Guideline Adherence | 2 | 2019 | 296 | 0.160 |
Why?
|
| Hemoglobinopathies | 2 | 1996 | 7 | 0.160 |
Why?
|
| Hemoglobins, Abnormal | 2 | 1996 | 6 | 0.160 |
Why?
|
| Frontotemporal Dementia | 1 | 2021 | 136 | 0.160 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 292 | 0.160 |
Why?
|
| Bronchoalveolar Lavage | 4 | 2023 | 14 | 0.160 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 1998 | 4 | 0.160 |
Why?
|
| Amino Acids | 2 | 2019 | 140 | 0.160 |
Why?
|
| Emergency Service, Hospital | 1 | 2007 | 1022 | 0.160 |
Why?
|
| Immunization | 1 | 1999 | 128 | 0.160 |
Why?
|
| Pulmonary Heart Disease | 1 | 1998 | 3 | 0.150 |
Why?
|
| Hemodynamics | 5 | 2018 | 230 | 0.150 |
Why?
|
| Exercise Therapy | 3 | 1997 | 99 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2018 | 7 | 0.150 |
Why?
|
| Essential Hypertension | 1 | 2018 | 1 | 0.150 |
Why?
|
| Smad2 Protein | 1 | 2018 | 8 | 0.150 |
Why?
|
| Receptor, ErbB-4 | 1 | 2018 | 9 | 0.150 |
Why?
|
| Vascular Calcification | 1 | 2018 | 22 | 0.150 |
Why?
|
| Methotrexate | 1 | 1999 | 76 | 0.150 |
Why?
|
| Troponin I | 1 | 2018 | 34 | 0.150 |
Why?
|
| Medical History Taking | 4 | 2005 | 65 | 0.150 |
Why?
|
| Apoptosis | 2 | 2014 | 1033 | 0.150 |
Why?
|
| Cholesterol | 1 | 2000 | 253 | 0.150 |
Why?
|
| Xanthines | 1 | 2018 | 8 | 0.150 |
Why?
|
| Hemoglobins | 3 | 2018 | 133 | 0.150 |
Why?
|
| California | 2 | 2021 | 161 | 0.150 |
Why?
|
| Hematologic Neoplasms | 1 | 1999 | 44 | 0.150 |
Why?
|
| Thrombosis | 2 | 2010 | 183 | 0.150 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2018 | 6 | 0.150 |
Why?
|
| Waste Disposal, Fluid | 1 | 2018 | 5 | 0.150 |
Why?
|
| Social Support | 1 | 2021 | 355 | 0.150 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2018 | 52 | 0.150 |
Why?
|
| Fibroblast Growth Factor 10 | 1 | 2018 | 2 | 0.150 |
Why?
|
| Proteinuria | 4 | 2009 | 38 | 0.150 |
Why?
|
| Gingival Neoplasms | 1 | 1998 | 2 | 0.150 |
Why?
|
| Betamethasone | 1 | 2018 | 5 | 0.150 |
Why?
|
| Waist Circumference | 2 | 2015 | 45 | 0.150 |
Why?
|
| Toxicity Tests | 1 | 2018 | 17 | 0.150 |
Why?
|
| Transplant Recipients | 2 | 2015 | 31 | 0.150 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2018 | 10 | 0.150 |
Why?
|
| Fetal Membranes, Premature Rupture | 1 | 2018 | 12 | 0.150 |
Why?
|
| Leukemia, Myeloid | 1 | 1998 | 32 | 0.150 |
Why?
|
| Graft vs Host Disease | 1 | 1999 | 105 | 0.150 |
Why?
|
| Pneumococcal Infections | 2 | 2012 | 35 | 0.150 |
Why?
|
| ErbB Receptors | 2 | 2022 | 112 | 0.150 |
Why?
|
| Metabolomics | 4 | 2021 | 49 | 0.150 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 1994 | 158 | 0.150 |
Why?
|
| Cellular Senescence | 1 | 2018 | 104 | 0.140 |
Why?
|
| Fragile X Mental Retardation Protein | 1 | 2018 | 38 | 0.140 |
Why?
|
| Dimensional Measurement Accuracy | 1 | 2017 | 2 | 0.140 |
Why?
|
| Protein Kinases | 1 | 2018 | 142 | 0.140 |
Why?
|
| Water Pollutants, Chemical | 1 | 2018 | 35 | 0.140 |
Why?
|
| Pulmonologists | 1 | 2017 | 4 | 0.140 |
Why?
|
| Obstetric Labor, Premature | 1 | 2018 | 31 | 0.140 |
Why?
|
| Bacteriological Techniques | 2 | 2014 | 28 | 0.140 |
Why?
|
| Regenerative Medicine | 1 | 2017 | 19 | 0.140 |
Why?
|
| Probability | 5 | 2022 | 168 | 0.140 |
Why?
|
| Quinolines | 3 | 2008 | 41 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2012 | 328 | 0.140 |
Why?
|
| Mucins | 1 | 2017 | 25 | 0.140 |
Why?
|
| Breast Feeding | 1 | 2000 | 144 | 0.140 |
Why?
|
| Lipopolysaccharides | 3 | 2010 | 627 | 0.140 |
Why?
|
| Whole Genome Sequencing | 3 | 2022 | 63 | 0.140 |
Why?
|
| Up-Regulation | 4 | 2021 | 365 | 0.140 |
Why?
|
| Translations | 1 | 2017 | 3 | 0.140 |
Why?
|
| Immunoglobulin A | 1 | 2018 | 94 | 0.140 |
Why?
|
| Hemoptysis | 1 | 1997 | 8 | 0.140 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 275 | 0.140 |
Why?
|
| Disease Susceptibility | 3 | 2020 | 157 | 0.140 |
Why?
|
| Early Medical Intervention | 1 | 2017 | 17 | 0.140 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2017 | 103 | 0.140 |
Why?
|
| Proteins | 4 | 2014 | 730 | 0.140 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2012 | 46 | 0.140 |
Why?
|
| Self Report | 2 | 2022 | 359 | 0.140 |
Why?
|
| Delphi Technique | 3 | 2025 | 77 | 0.140 |
Why?
|
| Bone Marrow | 1 | 2018 | 174 | 0.140 |
Why?
|
| Suspensions | 1 | 2016 | 9 | 0.140 |
Why?
|
| Blood Transfusion | 1 | 2018 | 150 | 0.140 |
Why?
|
| Helicobacter Infections | 1 | 2017 | 55 | 0.140 |
Why?
|
| Brain | 3 | 2021 | 1488 | 0.140 |
Why?
|
| D-Amino-Acid Oxidase | 1 | 2016 | 2 | 0.140 |
Why?
|
| Quality Improvement | 1 | 2021 | 418 | 0.140 |
Why?
|
| Helicobacter pylori | 1 | 2017 | 58 | 0.140 |
Why?
|
| Stress, Psychological | 1 | 2021 | 442 | 0.140 |
Why?
|
| Pancreatic Elastase | 2 | 2021 | 32 | 0.130 |
Why?
|
| Abdominal Pain | 2 | 2015 | 94 | 0.130 |
Why?
|
| Social Class | 3 | 2021 | 122 | 0.130 |
Why?
|
| Global Burden of Disease | 1 | 2016 | 9 | 0.130 |
Why?
|
| Pharmaceutical Preparations | 1 | 2018 | 117 | 0.130 |
Why?
|
| Contraindications | 5 | 2006 | 46 | 0.130 |
Why?
|
| Purines | 3 | 2013 | 38 | 0.130 |
Why?
|
| Multidetector Computed Tomography | 1 | 2016 | 20 | 0.130 |
Why?
|
| Mice, SCID | 3 | 2014 | 513 | 0.130 |
Why?
|
| Monocyte Chemoattractant Proteins | 2 | 2008 | 6 | 0.130 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2014 | 67 | 0.130 |
Why?
|
| TATA-Binding Protein Associated Factors | 1 | 2016 | 18 | 0.130 |
Why?
|
| Odds Ratio | 3 | 2025 | 747 | 0.130 |
Why?
|
| Diarrhea | 3 | 2022 | 75 | 0.130 |
Why?
|
| Poisson Distribution | 3 | 2012 | 52 | 0.130 |
Why?
|
| Fund Raising | 1 | 2016 | 7 | 0.130 |
Why?
|
| Polyadenylation | 1 | 2016 | 45 | 0.130 |
Why?
|
| Receptors, Interleukin | 3 | 2006 | 39 | 0.130 |
Why?
|
| Premature Birth | 1 | 2018 | 108 | 0.130 |
Why?
|
| Tobacco Use Disorder | 1 | 2019 | 243 | 0.130 |
Why?
|
| Proteome | 1 | 2017 | 141 | 0.130 |
Why?
|
| Mediastinal Neoplasms | 1 | 1996 | 17 | 0.130 |
Why?
|
| Gene-Environment Interaction | 1 | 2016 | 48 | 0.130 |
Why?
|
| Area Under Curve | 3 | 2016 | 141 | 0.130 |
Why?
|
| Tacrolimus | 3 | 2011 | 62 | 0.130 |
Why?
|
| Chest Tubes | 1 | 1996 | 16 | 0.130 |
Why?
|
| Antiphospholipid Syndrome | 2 | 2013 | 13 | 0.130 |
Why?
|
| Drug Delivery Systems | 1 | 2019 | 312 | 0.130 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2015 | 158 | 0.130 |
Why?
|
| Peptide Hydrolases | 1 | 2016 | 78 | 0.130 |
Why?
|
| Immunity, Innate | 2 | 2023 | 774 | 0.130 |
Why?
|
| Stroke | 2 | 2022 | 1128 | 0.130 |
Why?
|
| Aza Compounds | 2 | 2007 | 4 | 0.130 |
Why?
|
| RNA-Binding Protein FUS | 1 | 2016 | 53 | 0.130 |
Why?
|
| Nutrigenomics | 1 | 2015 | 3 | 0.130 |
Why?
|
| Preoperative Care | 4 | 2001 | 180 | 0.130 |
Why?
|
| CpG Islands | 2 | 2014 | 211 | 0.130 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2015 | 7 | 0.120 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 54 | 0.120 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 154 | 0.120 |
Why?
|
| Thioredoxins | 1 | 2015 | 16 | 0.120 |
Why?
|
| Cyclobutanes | 2 | 2025 | 4 | 0.120 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2015 | 22 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1999 | 402 | 0.120 |
Why?
|
| Catecholamines | 1 | 2015 | 29 | 0.120 |
Why?
|
| Organic Chemicals | 2 | 2025 | 22 | 0.120 |
Why?
|
| Ankyrin Repeat | 1 | 2015 | 1 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2015 | 10 | 0.120 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2015 | 14 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 5 | 2014 | 394 | 0.120 |
Why?
|
| Vitamin E | 1 | 2015 | 52 | 0.120 |
Why?
|
| Veterans | 1 | 2023 | 728 | 0.120 |
Why?
|
| Epitopes | 2 | 2013 | 286 | 0.120 |
Why?
|
| Connective Tissue Diseases | 2 | 2024 | 10 | 0.120 |
Why?
|
| Interleukin-15 | 2 | 2017 | 24 | 0.120 |
Why?
|
| Intention to Treat Analysis | 3 | 2020 | 18 | 0.120 |
Why?
|
| Housing | 1 | 2015 | 72 | 0.120 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2014 | 12 | 0.120 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2015 | 15 | 0.120 |
Why?
|
| Piperidines | 2 | 2025 | 55 | 0.120 |
Why?
|
| Th2 Cells | 1 | 2015 | 99 | 0.120 |
Why?
|
| Tissue Banks | 1 | 2014 | 4 | 0.120 |
Why?
|
| Subtraction Technique | 1 | 2014 | 23 | 0.120 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2007 | 191 | 0.120 |
Why?
|
| Thorax | 2 | 2022 | 34 | 0.120 |
Why?
|
| Informatics | 1 | 2014 | 10 | 0.120 |
Why?
|
| Medication Adherence | 2 | 2019 | 241 | 0.120 |
Why?
|
| Pattern Recognition, Automated | 1 | 2014 | 52 | 0.120 |
Why?
|
| alpha-N-Acetylgalactosaminidase | 1 | 2014 | 1 | 0.120 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 112 | 0.120 |
Why?
|
| Mexico | 1 | 2014 | 39 | 0.110 |
Why?
|
| Hospital Mortality | 3 | 2022 | 845 | 0.110 |
Why?
|
| CD56 Antigen | 1 | 2014 | 15 | 0.110 |
Why?
|
| Republic of Korea | 1 | 2014 | 29 | 0.110 |
Why?
|
| Receptors, Interleukin-4 | 2 | 2004 | 8 | 0.110 |
Why?
|
| Plasma | 2 | 2014 | 35 | 0.110 |
Why?
|
| Pseudomonas | 1 | 2014 | 7 | 0.110 |
Why?
|
| HLA-C Antigens | 1 | 2014 | 3 | 0.110 |
Why?
|
| Leukemia | 2 | 2012 | 57 | 0.110 |
Why?
|
| Free Radical Scavengers | 1 | 2014 | 18 | 0.110 |
Why?
|
| Fatty Acid Desaturases | 1 | 2014 | 9 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 29 | 0.110 |
Why?
|
| Streptococcus | 1 | 2014 | 17 | 0.110 |
Why?
|
| Nitrogen Dioxide | 2 | 2024 | 8 | 0.110 |
Why?
|
| Psychometrics | 1 | 2016 | 362 | 0.110 |
Why?
|
| Metabolome | 1 | 2014 | 27 | 0.110 |
Why?
|
| Postpoliomyelitis Syndrome | 1 | 1994 | 3 | 0.110 |
Why?
|
| Neurons | 2 | 2017 | 864 | 0.110 |
Why?
|
| Simvastatin | 1 | 2014 | 27 | 0.110 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 386 | 0.110 |
Why?
|
| Vocal Cord Paralysis | 1 | 1994 | 10 | 0.110 |
Why?
|
| Ikaros Transcription Factor | 1 | 2014 | 3 | 0.110 |
Why?
|
| Hyperinsulinism | 1 | 1994 | 25 | 0.110 |
Why?
|
| Laparoscopy | 1 | 2018 | 427 | 0.110 |
Why?
|
| Tracheal Diseases | 1 | 1994 | 12 | 0.110 |
Why?
|
| Collagen Type IV | 1 | 2013 | 3 | 0.110 |
Why?
|
| Phylogeny | 3 | 2024 | 337 | 0.110 |
Why?
|
| Edetic Acid | 1 | 2014 | 21 | 0.110 |
Why?
|
| Workplace | 1 | 2015 | 169 | 0.110 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2014 | 57 | 0.110 |
Why?
|
| Information Seeking Behavior | 1 | 2014 | 36 | 0.110 |
Why?
|
| Culture Techniques | 1 | 2013 | 12 | 0.110 |
Why?
|
| Anemia, Hemolytic | 1 | 1994 | 12 | 0.110 |
Why?
|
| Picornaviridae Infections | 1 | 2013 | 2 | 0.110 |
Why?
|
| Serum | 1 | 2014 | 28 | 0.110 |
Why?
|
| Mental Recall | 1 | 2014 | 88 | 0.110 |
Why?
|
| Models, Organizational | 1 | 2014 | 92 | 0.110 |
Why?
|
| Basement Membrane | 1 | 2013 | 25 | 0.110 |
Why?
|
| Methylprednisolone | 1 | 1994 | 32 | 0.110 |
Why?
|
| Cryptococcosis | 1 | 2015 | 76 | 0.110 |
Why?
|
| Elasticity | 1 | 2014 | 40 | 0.110 |
Why?
|
| Cell Line | 6 | 2020 | 1984 | 0.110 |
Why?
|
| Bayes Theorem | 3 | 2022 | 110 | 0.110 |
Why?
|
| Sex Distribution | 3 | 2012 | 244 | 0.110 |
Why?
|
| Atrial Fibrillation | 1 | 2022 | 805 | 0.110 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2014 | 170 | 0.110 |
Why?
|
| Disability Evaluation | 1 | 2015 | 199 | 0.110 |
Why?
|
| Adenosine Triphosphate | 1 | 2015 | 289 | 0.110 |
Why?
|
| Diagnostic Imaging | 2 | 2023 | 244 | 0.110 |
Why?
|
| Donor Selection | 2 | 2011 | 16 | 0.110 |
Why?
|
| Presenilin-1 | 1 | 2013 | 59 | 0.110 |
Why?
|
| Pulmonary Veins | 2 | 2009 | 37 | 0.110 |
Why?
|
| Heart-Lung Transplantation | 3 | 2003 | 7 | 0.110 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2013 | 7 | 0.110 |
Why?
|
| Endothelin A Receptor Antagonists | 1 | 2013 | 1 | 0.110 |
Why?
|
| Histamine H2 Antagonists | 1 | 2013 | 10 | 0.110 |
Why?
|
| Trans-Activators | 1 | 2015 | 300 | 0.110 |
Why?
|
| Respiratory Physiological Phenomena | 2 | 2023 | 11 | 0.110 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2013 | 69 | 0.110 |
Why?
|
| Cellular Reprogramming | 1 | 2013 | 35 | 0.110 |
Why?
|
| C-Reactive Protein | 3 | 2019 | 159 | 0.110 |
Why?
|
| Adaptive Clinical Trials as Topic | 2 | 2024 | 5 | 0.110 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2013 | 8 | 0.110 |
Why?
|
| Thrombocytopenia | 1 | 1994 | 45 | 0.110 |
Why?
|
| Heart Failure | 3 | 2014 | 853 | 0.110 |
Why?
|
| Proton Pump Inhibitors | 1 | 2013 | 33 | 0.100 |
Why?
|
| Pluripotent Stem Cells | 1 | 2013 | 68 | 0.100 |
Why?
|
| NADPH Oxidases | 2 | 2011 | 67 | 0.100 |
Why?
|
| Neurogenesis | 1 | 2013 | 60 | 0.100 |
Why?
|
| Rhinitis, Allergic, Seasonal | 3 | 2017 | 5 | 0.100 |
Why?
|
| Mannose-Binding Lectin | 1 | 2012 | 3 | 0.100 |
Why?
|
| HIV Infections | 2 | 2005 | 913 | 0.100 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2013 | 65 | 0.100 |
Why?
|
| Interviews as Topic | 3 | 2024 | 484 | 0.100 |
Why?
|
| Dogs | 2 | 1994 | 314 | 0.100 |
Why?
|
| Hemothorax | 1 | 1992 | 8 | 0.100 |
Why?
|
| HLA Antigens | 2 | 2010 | 61 | 0.100 |
Why?
|
| Autoantigens | 1 | 2013 | 129 | 0.100 |
Why?
|
| Age Distribution | 2 | 2007 | 249 | 0.100 |
Why?
|
| Safety | 3 | 2010 | 142 | 0.100 |
Why?
|
| Tomography, Emission-Computed | 1 | 2012 | 40 | 0.100 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2014 | 151 | 0.100 |
Why?
|
| Perception | 2 | 2012 | 168 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2010 | 490 | 0.100 |
Why?
|
| Isoantibodies | 2 | 2009 | 33 | 0.100 |
Why?
|
| Postoperative Period | 3 | 2006 | 127 | 0.100 |
Why?
|
| Drug Resistance, Microbial | 3 | 2001 | 47 | 0.100 |
Why?
|
| Pilot Projects | 3 | 2015 | 915 | 0.100 |
Why?
|
| RNA, Double-Stranded | 1 | 2013 | 106 | 0.100 |
Why?
|
| Fetal Proteins | 1 | 2012 | 8 | 0.100 |
Why?
|
| Subphrenic Abscess | 1 | 1992 | 5 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2012 | 85 | 0.100 |
Why?
|
| Genetic Loci | 3 | 2018 | 107 | 0.100 |
Why?
|
| Proteolysis | 1 | 2013 | 136 | 0.100 |
Why?
|
| Receptors, Notch | 1 | 2013 | 101 | 0.100 |
Why?
|
| T-Box Domain Proteins | 1 | 2012 | 37 | 0.100 |
Why?
|
| Splenic Diseases | 1 | 1992 | 15 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2019 | 295 | 0.100 |
Why?
|
| Shoulder | 1 | 1992 | 24 | 0.100 |
Why?
|
| Base Sequence | 4 | 2020 | 1302 | 0.100 |
Why?
|
| Southwestern United States | 1 | 2011 | 1 | 0.100 |
Why?
|
| Equipment Design | 3 | 2020 | 330 | 0.100 |
Why?
|
| Neuroprotective Agents | 1 | 2012 | 72 | 0.100 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 125 | 0.100 |
Why?
|
| Pleural Effusion | 1 | 1992 | 35 | 0.100 |
Why?
|
| Terminal Care | 1 | 2013 | 96 | 0.100 |
Why?
|
| Antibodies, Antinuclear | 1 | 1992 | 36 | 0.100 |
Why?
|
| Organ Dysfunction Scores | 2 | 2022 | 19 | 0.100 |
Why?
|
| Infant | 8 | 2019 | 1493 | 0.100 |
Why?
|
| Inspiratory Capacity | 1 | 2011 | 2 | 0.100 |
Why?
|
| Monitoring, Physiologic | 2 | 2025 | 149 | 0.100 |
Why?
|
| Patient Compliance | 4 | 2019 | 349 | 0.100 |
Why?
|
| Aorta | 1 | 2012 | 108 | 0.090 |
Why?
|
| Valine | 2 | 2019 | 31 | 0.090 |
Why?
|
| Body Fat Distribution | 1 | 2011 | 12 | 0.090 |
Why?
|
| Ontario | 1 | 2011 | 43 | 0.090 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2013 | 151 | 0.090 |
Why?
|
| Self-Assessment | 2 | 2010 | 60 | 0.090 |
Why?
|
| Molecular Sequence Data | 5 | 2015 | 1953 | 0.090 |
Why?
|
| Obesity, Abdominal | 1 | 2011 | 9 | 0.090 |
Why?
|
| Molecular Epidemiology | 2 | 2022 | 25 | 0.090 |
Why?
|
| Observer Variation | 4 | 2010 | 205 | 0.090 |
Why?
|
| Blood Flow Velocity | 1 | 2011 | 68 | 0.090 |
Why?
|
| Abscess | 1 | 1992 | 78 | 0.090 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2011 | 35 | 0.090 |
Why?
|
| Serine Endopeptidases | 2 | 2023 | 84 | 0.090 |
Why?
|
| Leukapheresis | 1 | 2011 | 8 | 0.090 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2011 | 6 | 0.090 |
Why?
|
| Cardiomyopathies | 1 | 2013 | 119 | 0.090 |
Why?
|
| Hydroxyurea | 1 | 2011 | 21 | 0.090 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2013 | 210 | 0.090 |
Why?
|
| Health | 1 | 2011 | 31 | 0.090 |
Why?
|
| Decision Making | 3 | 2018 | 395 | 0.090 |
Why?
|
| Movement | 2 | 1992 | 149 | 0.090 |
Why?
|
| Ion Channels | 1 | 2011 | 88 | 0.090 |
Why?
|
| Toll-Like Receptors | 1 | 2013 | 426 | 0.090 |
Why?
|
| Qualitative Research | 3 | 2024 | 619 | 0.090 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2010 | 4 | 0.090 |
Why?
|
| Pleural Diseases | 2 | 2005 | 8 | 0.090 |
Why?
|
| Matrix Metalloproteinases | 1 | 2010 | 16 | 0.090 |
Why?
|
| Models, Immunological | 2 | 2001 | 85 | 0.090 |
Why?
|
| Insulin Resistance | 1 | 1994 | 392 | 0.090 |
Why?
|
| DNA, Viral | 2 | 2010 | 223 | 0.090 |
Why?
|
| Mitochondrial Proteins | 1 | 2011 | 100 | 0.090 |
Why?
|
| Remission Induction | 2 | 2009 | 137 | 0.090 |
Why?
|
| Signal Transduction | 3 | 2013 | 2901 | 0.090 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2010 | 6 | 0.090 |
Why?
|
| Cardiac Catheterization | 2 | 2015 | 253 | 0.090 |
Why?
|
| Immunization, Passive | 2 | 2021 | 99 | 0.090 |
Why?
|
| Internet | 1 | 2014 | 448 | 0.090 |
Why?
|
| Residual Volume | 2 | 2009 | 3 | 0.090 |
Why?
|
| Epoxide Hydrolases | 2 | 2007 | 6 | 0.090 |
Why?
|
| Mitochondria | 3 | 2018 | 343 | 0.090 |
Why?
|
| Cluster Analysis | 3 | 2018 | 245 | 0.090 |
Why?
|
| Lymphatic Diseases | 1 | 1990 | 13 | 0.090 |
Why?
|
| Biological Variation, Population | 2 | 2020 | 9 | 0.090 |
Why?
|
| New York City | 2 | 2020 | 75 | 0.090 |
Why?
|
| Mediastinal Diseases | 1 | 1990 | 15 | 0.090 |
Why?
|
| Focus Groups | 3 | 2020 | 288 | 0.090 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2010 | 3 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2011 | 120 | 0.090 |
Why?
|
| Radiology | 1 | 2014 | 238 | 0.080 |
Why?
|
| Hypertension, Renal | 1 | 2010 | 4 | 0.080 |
Why?
|
| Infant, Newborn | 6 | 2018 | 1286 | 0.080 |
Why?
|
| Hospitals, Public | 1 | 2010 | 7 | 0.080 |
Why?
|
| National Health Programs | 1 | 2010 | 13 | 0.080 |
Why?
|
| Interleukin-18 | 1 | 2010 | 71 | 0.080 |
Why?
|
| Muscle Contraction | 2 | 1990 | 197 | 0.080 |
Why?
|
| Boronic Acids | 1 | 2010 | 28 | 0.080 |
Why?
|
| Pyrazines | 1 | 2010 | 33 | 0.080 |
Why?
|
| Sickness Impact Profile | 1 | 2009 | 47 | 0.080 |
Why?
|
| Neuroblastoma | 1 | 2010 | 48 | 0.080 |
Why?
|
| Poverty | 2 | 2022 | 283 | 0.080 |
Why?
|
| Homozygote | 2 | 2018 | 114 | 0.080 |
Why?
|
| Leishmaniasis, Cutaneous | 3 | 1993 | 15 | 0.080 |
Why?
|
| Energy Metabolism | 4 | 2011 | 359 | 0.080 |
Why?
|
| Hypothyroidism | 1 | 1989 | 39 | 0.080 |
Why?
|
| Antibody Specificity | 1 | 2009 | 100 | 0.080 |
Why?
|
| Gastric Emptying | 1 | 2009 | 6 | 0.080 |
Why?
|
| Models, Biological | 2 | 2014 | 1143 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 454 | 0.080 |
Why?
|
| Gastroparesis | 1 | 2009 | 8 | 0.080 |
Why?
|
| Respiratory Sounds | 2 | 2008 | 22 | 0.080 |
Why?
|
| Dobutamine | 2 | 1999 | 8 | 0.080 |
Why?
|
| Hydrogen Peroxide | 2 | 2009 | 76 | 0.080 |
Why?
|
| Mass Spectrometry | 3 | 2017 | 295 | 0.080 |
Why?
|
| Heart Valve Prosthesis | 3 | 1986 | 92 | 0.080 |
Why?
|
| Neutropenia | 1 | 2009 | 62 | 0.080 |
Why?
|
| Mesoderm | 1 | 2009 | 81 | 0.080 |
Why?
|
| Pain | 1 | 1992 | 397 | 0.080 |
Why?
|
| Haemophilus influenzae | 2 | 2007 | 26 | 0.080 |
Why?
|
| Quantitative Trait Loci | 2 | 2021 | 70 | 0.080 |
Why?
|
| Vaccination | 1 | 2011 | 335 | 0.080 |
Why?
|
| Carcinoma, Bronchogenic | 3 | 1997 | 7 | 0.080 |
Why?
|
| Health Education | 2 | 2007 | 183 | 0.080 |
Why?
|
| Confidence Intervals | 2 | 2006 | 241 | 0.080 |
Why?
|
| Cytoskeletal Proteins | 1 | 2010 | 196 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2010 | 245 | 0.080 |
Why?
|
| Interleukin-4 | 3 | 2008 | 145 | 0.080 |
Why?
|
| Pregnancy | 4 | 2018 | 2215 | 0.080 |
Why?
|
| Ventilation-Perfusion Ratio | 2 | 2006 | 11 | 0.080 |
Why?
|
| Health Resources | 1 | 2009 | 88 | 0.070 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2006 | 16 | 0.070 |
Why?
|
| Lymphocyte Depletion | 3 | 2013 | 99 | 0.070 |
Why?
|
| RNA | 2 | 2022 | 402 | 0.070 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 2 | 2019 | 30 | 0.070 |
Why?
|
| Renin | 1 | 2008 | 10 | 0.070 |
Why?
|
| Actins | 5 | 2008 | 259 | 0.070 |
Why?
|
| Carbon Dioxide | 4 | 1999 | 84 | 0.070 |
Why?
|
| Fertility | 1 | 2008 | 78 | 0.070 |
Why?
|
| Infertility, Male | 1 | 2008 | 57 | 0.070 |
Why?
|
| Inflammasomes | 1 | 2012 | 324 | 0.070 |
Why?
|
| Bronchiectasis | 1 | 2008 | 7 | 0.070 |
Why?
|
| Nausea | 2 | 2007 | 110 | 0.070 |
Why?
|
| Self Efficacy | 1 | 2009 | 194 | 0.070 |
Why?
|
| Fluoroquinolones | 2 | 2007 | 31 | 0.070 |
Why?
|
| Fibronectins | 1 | 2007 | 43 | 0.070 |
Why?
|
| Cross-Over Studies | 2 | 2019 | 153 | 0.070 |
Why?
|
| Dinoprostone | 1 | 2007 | 44 | 0.070 |
Why?
|
| Antigens, CD | 4 | 2010 | 343 | 0.070 |
Why?
|
| Emotions | 1 | 2010 | 215 | 0.070 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 2020 | 42 | 0.070 |
Why?
|
| Positive-Pressure Respiration | 1 | 2007 | 46 | 0.070 |
Why?
|
| Steroids | 1 | 2007 | 52 | 0.070 |
Why?
|
| Socioeconomic Factors | 3 | 2021 | 742 | 0.070 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2007 | 5 | 0.070 |
Why?
|
| Life Expectancy | 1 | 2007 | 34 | 0.070 |
Why?
|
| Cell Proliferation | 4 | 2016 | 942 | 0.070 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2007 | 10 | 0.070 |
Why?
|
| Reticulocytes | 1 | 2007 | 12 | 0.070 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2011 | 83 | 0.070 |
Why?
|
| Phosphorylation | 3 | 2012 | 885 | 0.070 |
Why?
|
| Dermatitis, Atopic | 2 | 1999 | 27 | 0.070 |
Why?
|
| Communication | 1 | 2011 | 547 | 0.070 |
Why?
|
| Feasibility Studies | 3 | 2019 | 526 | 0.070 |
Why?
|
| Drug Synergism | 2 | 2012 | 132 | 0.070 |
Why?
|
| Adoptive Transfer | 1 | 2007 | 147 | 0.070 |
Why?
|
| Drug Monitoring | 2 | 2020 | 115 | 0.070 |
Why?
|
| Hormones | 2 | 2005 | 60 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2015 | 588 | 0.070 |
Why?
|
| Overweight | 2 | 2022 | 238 | 0.070 |
Why?
|
| Software | 2 | 2001 | 366 | 0.070 |
Why?
|
| Urinary Bladder Diseases | 1 | 2006 | 9 | 0.070 |
Why?
|
| Awareness | 1 | 2007 | 74 | 0.070 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2006 | 7 | 0.070 |
Why?
|
| Postmenopause | 1 | 2008 | 224 | 0.070 |
Why?
|
| Verapamil | 1 | 1986 | 9 | 0.060 |
Why?
|
| Dendritic Cells | 1 | 2009 | 515 | 0.060 |
Why?
|
| Atenolol | 1 | 1986 | 9 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2007 | 103 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2006 | 90 | 0.060 |
Why?
|
| Thyroid Gland | 1 | 2006 | 79 | 0.060 |
Why?
|
| Microspheres | 1 | 2005 | 55 | 0.060 |
Why?
|
| 3' Untranslated Regions | 2 | 2016 | 89 | 0.060 |
Why?
|
| Amoxicillin-Potassium Clavulanate Combination | 1 | 2005 | 1 | 0.060 |
Why?
|
| Latin America | 2 | 2018 | 13 | 0.060 |
Why?
|
| Metaplasia | 1 | 2005 | 18 | 0.060 |
Why?
|
| Progestins | 1 | 2005 | 29 | 0.060 |
Why?
|
| Endometrium | 1 | 2005 | 28 | 0.060 |
Why?
|
| Japan | 2 | 2018 | 51 | 0.060 |
Why?
|
| Cardiotonic Agents | 2 | 2010 | 50 | 0.060 |
Why?
|
| Microcirculation | 1 | 2005 | 52 | 0.060 |
Why?
|
| Tablets | 1 | 2025 | 16 | 0.060 |
Why?
|
| Chromosome Mapping | 2 | 2018 | 284 | 0.060 |
Why?
|
| Paris | 2 | 2010 | 5 | 0.060 |
Why?
|
| Liver Transplantation | 2 | 2010 | 207 | 0.060 |
Why?
|
| Health Care Surveys | 2 | 2005 | 279 | 0.060 |
Why?
|
| Aortic Valve | 2 | 1986 | 173 | 0.060 |
Why?
|
| Injections, Subcutaneous | 1 | 2025 | 69 | 0.060 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2005 | 83 | 0.060 |
Why?
|
| Physical Exertion | 2 | 1996 | 79 | 0.060 |
Why?
|
| Scleroderma, Diffuse | 1 | 2004 | 2 | 0.060 |
Why?
|
| Nitrogen Oxides | 1 | 2024 | 7 | 0.060 |
Why?
|
| Blood Glucose | 2 | 2020 | 461 | 0.060 |
Why?
|
| Calcium Channel Blockers | 2 | 2010 | 57 | 0.060 |
Why?
|
| Estrogens | 1 | 2005 | 109 | 0.060 |
Why?
|
| Anaerobic Threshold | 2 | 1995 | 12 | 0.060 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2005 | 26 | 0.060 |
Why?
|
| Naphthyridines | 1 | 2004 | 6 | 0.060 |
Why?
|
| Autoimmune Diseases | 1 | 2006 | 220 | 0.060 |
Why?
|
| NADPH Oxidase 4 | 2 | 2017 | 6 | 0.060 |
Why?
|
| Peptides | 1 | 2008 | 549 | 0.060 |
Why?
|
| Bronchial Diseases | 2 | 1995 | 12 | 0.060 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 413 | 0.060 |
Why?
|
| Hypersensitivity | 2 | 2008 | 63 | 0.060 |
Why?
|
| Mouth | 1 | 2024 | 33 | 0.060 |
Why?
|
| Theophylline | 2 | 2018 | 9 | 0.060 |
Why?
|
| Hepatorenal Syndrome | 1 | 2003 | 2 | 0.060 |
Why?
|
| Hemorrhage | 3 | 2022 | 260 | 0.060 |
Why?
|
| Liver Failure | 1 | 2003 | 17 | 0.050 |
Why?
|
| Ascites | 1 | 2003 | 21 | 0.050 |
Why?
|
| Hepatic Encephalopathy | 1 | 2003 | 8 | 0.050 |
Why?
|
| Bleomycin | 3 | 2012 | 32 | 0.050 |
Why?
|
| Leishmania braziliensis | 2 | 1993 | 3 | 0.050 |
Why?
|
| Hydrochlorothiazide | 1 | 2003 | 3 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 197 | 0.050 |
Why?
|
| Radionuclide Imaging | 2 | 2009 | 121 | 0.050 |
Why?
|
| Oxyhemoglobins | 1 | 2003 | 9 | 0.050 |
Why?
|
| Skin Tests | 3 | 1999 | 21 | 0.050 |
Why?
|
| Alarmins | 1 | 2023 | 4 | 0.050 |
Why?
|
| Tetrazoles | 1 | 2003 | 21 | 0.050 |
Why?
|
| Cities | 1 | 2023 | 23 | 0.050 |
Why?
|
| Costa Rica | 2 | 2014 | 5 | 0.050 |
Why?
|
| Unsupervised Machine Learning | 1 | 2023 | 2 | 0.050 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2024 | 75 | 0.050 |
Why?
|
| Cell Death | 1 | 2005 | 271 | 0.050 |
Why?
|
| Proprotein Convertases | 1 | 2023 | 5 | 0.050 |
Why?
|
| Societies | 1 | 2023 | 23 | 0.050 |
Why?
|
| Gastroenterology | 1 | 2003 | 35 | 0.050 |
Why?
|
| Professional Practice Gaps | 1 | 2023 | 4 | 0.050 |
Why?
|
| Family Characteristics | 1 | 2023 | 43 | 0.050 |
Why?
|
| Introns | 2 | 2016 | 104 | 0.050 |
Why?
|
| In Vitro Techniques | 2 | 2015 | 473 | 0.050 |
Why?
|
| Virulence | 2 | 2020 | 188 | 0.050 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2003 | 15 | 0.050 |
Why?
|
| Aluminum Oxide | 1 | 2022 | 4 | 0.050 |
Why?
|
| Opportunistic Infections | 2 | 2001 | 29 | 0.050 |
Why?
|
| Personnel Selection | 1 | 2023 | 50 | 0.050 |
Why?
|
| Cotinine | 1 | 2022 | 19 | 0.050 |
Why?
|
| Soot | 1 | 2022 | 8 | 0.050 |
Why?
|
| Chemokine CCL21 | 3 | 2007 | 4 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 2 | 2016 | 418 | 0.050 |
Why?
|
| Receptors, CCR7 | 3 | 2007 | 9 | 0.050 |
Why?
|
| Reference Values | 2 | 2018 | 326 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2018 | 118 | 0.050 |
Why?
|
| Nifedipine | 2 | 2001 | 19 | 0.050 |
Why?
|
| Maximal Midexpiratory Flow Rate | 2 | 2020 | 3 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2023 | 191 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 2016 | 850 | 0.050 |
Why?
|
| Self Disclosure | 1 | 2002 | 37 | 0.050 |
Why?
|
| Oscillometry | 2 | 2015 | 13 | 0.050 |
Why?
|
| Carbon | 1 | 2022 | 45 | 0.050 |
Why?
|
| Baroreflex | 1 | 2022 | 19 | 0.050 |
Why?
|
| Sclerosis | 1 | 2022 | 7 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2024 | 309 | 0.050 |
Why?
|
| Hand Strength | 1 | 2022 | 28 | 0.050 |
Why?
|
| Ion Transport | 1 | 2022 | 19 | 0.050 |
Why?
|
| Exome | 1 | 2022 | 73 | 0.050 |
Why?
|
| Antibodies, Antiphospholipid | 2 | 2013 | 11 | 0.050 |
Why?
|
| Adenosine | 1 | 2022 | 70 | 0.050 |
Why?
|
| Africa | 2 | 1998 | 21 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2015 | 587 | 0.050 |
Why?
|
| Lymphangioleiomyomatosis | 2 | 2015 | 4 | 0.050 |
Why?
|
| Coagulase | 1 | 2001 | 1 | 0.050 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 1993 | 65 | 0.050 |
Why?
|
| Physical Examination | 2 | 2000 | 104 | 0.050 |
Why?
|
| Oxacillin | 1 | 2001 | 5 | 0.050 |
Why?
|
| Vasoconstrictor Agents | 1 | 2022 | 64 | 0.050 |
Why?
|
| Blood | 1 | 2001 | 29 | 0.050 |
Why?
|
| Secondary Care | 1 | 2021 | 2 | 0.050 |
Why?
|
| Methicillin Resistance | 1 | 2001 | 22 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 1 | 2022 | 61 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2002 | 149 | 0.050 |
Why?
|
| Urine | 1 | 2001 | 38 | 0.050 |
Why?
|
| Faculty, Medical | 1 | 2023 | 192 | 0.050 |
Why?
|
| Reactive Nitrogen Species | 1 | 2021 | 8 | 0.050 |
Why?
|
| Leadership | 1 | 2023 | 195 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2021 | 61 | 0.050 |
Why?
|
| Mitral Valve | 3 | 1998 | 105 | 0.050 |
Why?
|
| Protein Aggregation, Pathological | 1 | 2021 | 18 | 0.050 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 2 | 2012 | 5 | 0.050 |
Why?
|
| Single-Blind Method | 2 | 2014 | 136 | 0.050 |
Why?
|
| Podocytes | 1 | 2021 | 9 | 0.050 |
Why?
|
| Amino Acid Sequence | 3 | 2013 | 1555 | 0.050 |
Why?
|
| Receptors, Interleukin-13 | 3 | 2006 | 4 | 0.050 |
Why?
|
| Interleukin-13 Receptor alpha1 Subunit | 3 | 2006 | 4 | 0.050 |
Why?
|
| Autonomic Nervous System | 1 | 2021 | 34 | 0.050 |
Why?
|
| Immunologic Tests | 1 | 2001 | 5 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 66 | 0.050 |
Why?
|
| Cross Reactions | 1 | 2021 | 127 | 0.050 |
Why?
|
| Spironolactone | 1 | 2001 | 9 | 0.040 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2020 | 5 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2022 | 197 | 0.040 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2001 | 12 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2021 | 136 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2011 | 62 | 0.040 |
Why?
|
| Coronary Disease | 2 | 1999 | 244 | 0.040 |
Why?
|
| Aspergillosis | 1 | 2001 | 40 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2020 | 85 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2001 | 242 | 0.040 |
Why?
|
| Furin | 1 | 2020 | 10 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 2020 | 18 | 0.040 |
Why?
|
| Exhalation | 1 | 2020 | 15 | 0.040 |
Why?
|
| Cysteine | 1 | 2021 | 107 | 0.040 |
Why?
|
| Ferritins | 1 | 2020 | 30 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2002 | 143 | 0.040 |
Why?
|
| Caregivers | 1 | 2023 | 231 | 0.040 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2021 | 89 | 0.040 |
Why?
|
| Isoelectric Focusing | 1 | 2020 | 9 | 0.040 |
Why?
|
| DNA, Recombinant | 1 | 2020 | 44 | 0.040 |
Why?
|
| Staphylococcal Infections | 1 | 2001 | 124 | 0.040 |
Why?
|
| Vero Cells | 1 | 2020 | 76 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2003 | 428 | 0.040 |
Why?
|
| Models, Animal | 1 | 2021 | 222 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2012 | 584 | 0.040 |
Why?
|
| Infant Food | 1 | 2000 | 3 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2020 | 111 | 0.040 |
Why?
|
| Angina, Unstable | 1 | 2020 | 57 | 0.040 |
Why?
|
| Protein Interaction Mapping | 1 | 2020 | 67 | 0.040 |
Why?
|
| Colorado | 1 | 2000 | 19 | 0.040 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 1999 | 205 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2021 | 187 | 0.040 |
Why?
|
| Cell Division | 3 | 2007 | 443 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2021 | 215 | 0.040 |
Why?
|
| Airway Remodeling | 1 | 2019 | 7 | 0.040 |
Why?
|
| Canada | 2 | 2015 | 147 | 0.040 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 2010 | 105 | 0.040 |
Why?
|
| Antifibrinolytic Agents | 1 | 2019 | 15 | 0.040 |
Why?
|
| Echocardiography | 3 | 2013 | 458 | 0.040 |
Why?
|
| Isoleucine | 1 | 2019 | 9 | 0.040 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2019 | 12 | 0.040 |
Why?
|
| Choice Behavior | 1 | 2020 | 78 | 0.040 |
Why?
|
| Airway Resistance | 2 | 1994 | 11 | 0.040 |
Why?
|
| Joint Capsule Release | 1 | 2019 | 1 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 39 | 0.040 |
Why?
|
| Placenta | 1 | 2000 | 55 | 0.040 |
Why?
|
| Germ-Free Life | 1 | 2019 | 8 | 0.040 |
Why?
|
| Tryptophan | 1 | 2019 | 54 | 0.040 |
Why?
|
| Allergists | 1 | 2019 | 1 | 0.040 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2019 | 19 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2022 | 345 | 0.040 |
Why?
|
| Lectins, C-Type | 2 | 2010 | 88 | 0.040 |
Why?
|
| Leucine | 1 | 2019 | 61 | 0.040 |
Why?
|
| Immunomagnetic Separation | 1 | 1999 | 9 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2021 | 185 | 0.040 |
Why?
|
| Wound Healing | 2 | 2012 | 174 | 0.040 |
Why?
|
| Histocompatibility Testing | 1 | 1999 | 31 | 0.040 |
Why?
|
| Maximal Expiratory Flow-Volume Curves | 2 | 1996 | 2 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2019 | 23 | 0.040 |
Why?
|
| Postoperative Care | 2 | 2001 | 115 | 0.040 |
Why?
|
| Sleep | 1 | 2022 | 215 | 0.040 |
Why?
|
| West Indies | 1 | 1998 | 6 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 55 | 0.040 |
Why?
|
| Research | 1 | 2020 | 188 | 0.040 |
Why?
|
| Tidal Volume | 2 | 1996 | 37 | 0.040 |
Why?
|
| Catalase | 2 | 2011 | 23 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2000 | 365 | 0.040 |
Why?
|
| Muscular Diseases | 1 | 1999 | 46 | 0.040 |
Why?
|
| Rural Population | 3 | 2015 | 188 | 0.040 |
Why?
|
| Erectile Dysfunction | 1 | 1998 | 23 | 0.040 |
Why?
|
| Sarcoidosis | 1 | 1999 | 30 | 0.040 |
Why?
|
| Telomere Homeostasis | 1 | 2018 | 4 | 0.040 |
Why?
|
| Virus Replication | 1 | 2020 | 305 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2018 | 43 | 0.040 |
Why?
|
| Pedigree | 2 | 1996 | 183 | 0.040 |
Why?
|
| Evidence-Based Practice | 1 | 2019 | 79 | 0.040 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 1998 | 43 | 0.040 |
Why?
|
| Milk, Human | 1 | 2000 | 88 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 2 | 2012 | 868 | 0.040 |
Why?
|
| Tomography, Spiral Computed | 1 | 2018 | 21 | 0.040 |
Why?
|
| Occupational Health | 1 | 2020 | 181 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 1998 | 6 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1998 | 9 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1998 | 16 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 1998 | 8 | 0.040 |
Why?
|
| Psoriasis | 1 | 2018 | 50 | 0.040 |
Why?
|
| Chest Pain | 1 | 2019 | 81 | 0.040 |
Why?
|
| Home Care Services, Hospital-Based | 1 | 1998 | 5 | 0.040 |
Why?
|
| Alphaproteobacteria | 1 | 2018 | 1 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1998 | 13 | 0.040 |
Why?
|
| Sewage | 1 | 2018 | 5 | 0.040 |
Why?
|
| Betaproteobacteria | 1 | 2018 | 6 | 0.040 |
Why?
|
| Microbial Consortia | 1 | 2018 | 8 | 0.040 |
Why?
|
| Diffusion | 2 | 2010 | 82 | 0.040 |
Why?
|
| Medicare | 1 | 2022 | 601 | 0.040 |
Why?
|
| Tissue and Organ Procurement | 2 | 2009 | 37 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 1999 | 354 | 0.040 |
Why?
|
| Physicians, Primary Care | 1 | 2019 | 75 | 0.040 |
Why?
|
| Maxilla | 1 | 1998 | 3 | 0.040 |
Why?
|
| Genetic Linkage | 1 | 1998 | 93 | 0.040 |
Why?
|
| Bronchial Neoplasms | 1 | 1998 | 6 | 0.040 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 1998 | 9 | 0.040 |
Why?
|
| Geography | 1 | 2018 | 32 | 0.040 |
Why?
|
| Pulmonary Embolism | 2 | 2009 | 169 | 0.040 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 1997 | 2 | 0.040 |
Why?
|
| Total Quality Management | 1 | 1998 | 56 | 0.040 |
Why?
|
| Carboxyhemoglobin | 1 | 2017 | 12 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 480 | 0.040 |
Why?
|
| Histone Code | 1 | 2017 | 26 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 113 | 0.040 |
Why?
|
| Critical Illness | 1 | 2021 | 329 | 0.040 |
Why?
|
| Macrophages | 2 | 2022 | 1015 | 0.040 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2017 | 14 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2017 | 32 | 0.040 |
Why?
|
| Liver Abscess, Amebic | 1 | 1997 | 4 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 205 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 191 | 0.040 |
Why?
|
| Mitral Valve Insufficiency | 1 | 1998 | 74 | 0.040 |
Why?
|
| Liver Regeneration | 1 | 2017 | 18 | 0.040 |
Why?
|
| Entamoebiasis | 1 | 1997 | 2 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 1998 | 116 | 0.040 |
Why?
|
| Neoplasms, Second Primary | 1 | 1998 | 43 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 171 | 0.040 |
Why?
|
| Drug Utilization Review | 1 | 2018 | 52 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2020 | 222 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2017 | 53 | 0.040 |
Why?
|
| Antigen-Antibody Complex | 1 | 1997 | 51 | 0.040 |
Why?
|
| Review Literature as Topic | 1 | 2017 | 33 | 0.040 |
Why?
|
| Adrenergic beta-2 Receptor Antagonists | 1 | 2017 | 1 | 0.040 |
Why?
|
| Patient Safety | 1 | 2020 | 238 | 0.040 |
Why?
|
| Hospitals, Community | 1 | 2018 | 70 | 0.040 |
Why?
|
| Microarray Analysis | 1 | 2017 | 60 | 0.030 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 858 | 0.030 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1997 | 3 | 0.030 |
Why?
|
| Glomerulonephritis | 1 | 1997 | 31 | 0.030 |
Why?
|
| Radiographic Image Enhancement | 2 | 2014 | 98 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 409 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2017 | 34 | 0.030 |
Why?
|
| Stroke Volume | 2 | 2011 | 314 | 0.030 |
Why?
|
| Placebo Effect | 1 | 2017 | 10 | 0.030 |
Why?
|
| New Zealand | 1 | 2017 | 37 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 1998 | 129 | 0.030 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 2016 | 3 | 0.030 |
Why?
|
| Causality | 1 | 2017 | 57 | 0.030 |
Why?
|
| Cryptosporidium parvum | 1 | 1996 | 8 | 0.030 |
Why?
|
| Cryptosporidiosis | 1 | 1996 | 10 | 0.030 |
Why?
|
| Natriuresis | 2 | 1994 | 7 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1997 | 73 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2017 | 74 | 0.030 |
Why?
|
| Rats | 2 | 2013 | 1911 | 0.030 |
Why?
|
| ABO Blood-Group System | 1 | 2016 | 2 | 0.030 |
Why?
|
| Australia | 1 | 2017 | 86 | 0.030 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2016 | 5 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 1997 | 55 | 0.030 |
Why?
|
| I-kappa B Proteins | 1 | 2016 | 39 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 32 | 0.030 |
Why?
|
| Long-Term Care | 1 | 2018 | 177 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 1998 | 275 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2016 | 15 | 0.030 |
Why?
|
| Immunity, Mucosal | 1 | 1996 | 49 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2016 | 32 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1997 | 164 | 0.030 |
Why?
|
| Maximal Voluntary Ventilation | 1 | 1996 | 1 | 0.030 |
Why?
|
| Cathepsins | 1 | 2016 | 34 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 1998 | 210 | 0.030 |
Why?
|
| Cell Culture Techniques | 2 | 2009 | 178 | 0.030 |
Why?
|
| Microscopy, Electron | 2 | 2012 | 248 | 0.030 |
Why?
|
| Autophagy | 1 | 2018 | 213 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2018 | 181 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2016 | 75 | 0.030 |
Why?
|
| Lectins | 1 | 2016 | 40 | 0.030 |
Why?
|
| Sensation | 1 | 1996 | 19 | 0.030 |
Why?
|
| Antibodies, Bacterial | 1 | 2017 | 187 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2017 | 196 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 1996 | 74 | 0.030 |
Why?
|
| Cysteine Endopeptidases | 1 | 2016 | 92 | 0.030 |
Why?
|
| Coproporphyria, Hereditary | 1 | 2015 | 1 | 0.030 |
Why?
|
| Belgium | 1 | 2015 | 6 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2015 | 17 | 0.030 |
Why?
|
| Research Support as Topic | 1 | 2016 | 39 | 0.030 |
Why?
|
| Prenatal Care | 1 | 2018 | 170 | 0.030 |
Why?
|
| Porphyrias | 1 | 2015 | 2 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2015 | 24 | 0.030 |
Why?
|
| Antimetabolites | 1 | 2015 | 17 | 0.030 |
Why?
|
| Netherlands | 1 | 2015 | 22 | 0.030 |
Why?
|
| Germany | 1 | 2015 | 52 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 194 | 0.030 |
Why?
|
| World Health Organization | 1 | 2015 | 30 | 0.030 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1998 | 167 | 0.030 |
Why?
|
| Anthropometry | 1 | 2015 | 78 | 0.030 |
Why?
|
| Sialoglycoproteins | 1 | 1995 | 21 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1997 | 276 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 1999 | 430 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1997 | 147 | 0.030 |
Why?
|
| Workflow | 1 | 2015 | 63 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2015 | 61 | 0.030 |
Why?
|
| Body Composition | 1 | 2016 | 146 | 0.030 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2015 | 7 | 0.030 |
Why?
|
| Tracheal Stenosis | 1 | 1995 | 9 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 14 | 0.030 |
Why?
|
| Ligands | 2 | 2007 | 411 | 0.030 |
Why?
|
| Sodium Chloride | 2 | 1994 | 60 | 0.030 |
Why?
|
| Blood Pressure Determination | 1 | 2015 | 37 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1995 | 66 | 0.030 |
Why?
|
| Adalimumab | 1 | 2015 | 30 | 0.030 |
Why?
|
| Brachial Artery | 1 | 2015 | 28 | 0.030 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2015 | 14 | 0.030 |
Why?
|
| Program Development | 1 | 2016 | 203 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2016 | 137 | 0.030 |
Why?
|
| Policy Making | 1 | 2015 | 45 | 0.030 |
Why?
|
| RNA Helicases | 1 | 2015 | 88 | 0.030 |
Why?
|
| Cyanosis | 1 | 1994 | 6 | 0.030 |
Why?
|
| Suction | 1 | 1994 | 33 | 0.030 |
Why?
|
| Outpatients | 1 | 2016 | 137 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 263 | 0.030 |
Why?
|
| Globins | 1 | 1994 | 25 | 0.030 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2014 | 7 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 1995 | 157 | 0.030 |
Why?
|
| Methylene Blue | 1 | 1994 | 22 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2015 | 193 | 0.030 |
Why?
|
| Neprilysin | 1 | 1994 | 11 | 0.030 |
Why?
|
| DNA, Ribosomal | 1 | 2014 | 29 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 121 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2014 | 66 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2010 | 147 | 0.030 |
Why?
|
| Tracheal Neoplasms | 1 | 1994 | 4 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2015 | 333 | 0.030 |
Why?
|
| Chondrosarcoma | 1 | 1994 | 7 | 0.030 |
Why?
|
| Radial Artery | 1 | 2015 | 49 | 0.030 |
Why?
|
| Malaria Vaccines | 1 | 1994 | 27 | 0.030 |
Why?
|
| Radiopharmaceuticals | 2 | 2009 | 181 | 0.030 |
Why?
|
| Patient Discharge | 1 | 1998 | 492 | 0.030 |
Why?
|
| Psychophysiologic Disorders | 1 | 1994 | 7 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2014 | 17 | 0.030 |
Why?
|
| Carbon Tetrachloride | 1 | 2013 | 9 | 0.030 |
Why?
|
| Sodium | 1 | 1994 | 60 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2014 | 23 | 0.030 |
Why?
|
| Bronchial Hyperreactivity | 1 | 1994 | 29 | 0.030 |
Why?
|
| Neutrophils | 1 | 1996 | 365 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 1999 | 628 | 0.030 |
Why?
|
| Fructose | 1 | 1994 | 36 | 0.030 |
Why?
|
| Ultrasonography | 1 | 1996 | 458 | 0.030 |
Why?
|
| Occupational Exposure | 2 | 2013 | 307 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 2053 | 0.030 |
Why?
|
| Protozoan Proteins | 1 | 1994 | 86 | 0.030 |
Why?
|
| Family | 1 | 2015 | 229 | 0.030 |
Why?
|
| Physical Fitness | 1 | 1994 | 92 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 329 | 0.030 |
Why?
|
| Vesicular Transport Proteins | 1 | 2014 | 106 | 0.030 |
Why?
|
| Plasmapheresis | 1 | 2013 | 18 | 0.030 |
Why?
|
| Placebos | 1 | 2013 | 68 | 0.030 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2008 | 62 | 0.030 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2013 | 78 | 0.030 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2013 | 29 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2017 | 514 | 0.030 |
Why?
|
| Laser Coagulation | 1 | 1993 | 14 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 57 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2015 | 459 | 0.030 |
Why?
|
| Protease Inhibitors | 1 | 2014 | 104 | 0.030 |
Why?
|
| Cecum | 1 | 2012 | 13 | 0.030 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2012 | 9 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2012 | 16 | 0.030 |
Why?
|
| Pleural Neoplasms | 1 | 1992 | 19 | 0.030 |
Why?
|
| Spectrophotometry, Atomic | 1 | 2012 | 7 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 56 | 0.030 |
Why?
|
| Synovitis | 1 | 1993 | 30 | 0.030 |
Why?
|
| Intelligence Tests | 1 | 2012 | 25 | 0.030 |
Why?
|
| Observation | 1 | 2012 | 29 | 0.030 |
Why?
|
| Punctures | 1 | 1992 | 56 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2012 | 42 | 0.030 |
Why?
|
| Triglycerides | 1 | 1994 | 231 | 0.030 |
Why?
|
| Length of Stay | 2 | 2011 | 779 | 0.020 |
Why?
|
| Arteriovenous Malformations | 1 | 1992 | 43 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2017 | 683 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2012 | 31 | 0.020 |
Why?
|
| Aortography | 1 | 2012 | 55 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 2 | 2006 | 103 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 38 | 0.020 |
Why?
|
| Sweden | 1 | 2012 | 42 | 0.020 |
Why?
|
| Aortic Rupture | 1 | 1992 | 54 | 0.020 |
Why?
|
| Gastric Fistula | 1 | 1992 | 4 | 0.020 |
Why?
|
| Thoracic Injuries | 1 | 1992 | 46 | 0.020 |
Why?
|
| Splenic Neoplasms | 1 | 1992 | 8 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2014 | 240 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2013 | 354 | 0.020 |
Why?
|
| Collagen | 1 | 2012 | 115 | 0.020 |
Why?
|
| Interferon-gamma | 2 | 2004 | 551 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2013 | 169 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2013 | 259 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 169 | 0.020 |
Why?
|
| Hyperlipidemia, Familial Combined | 1 | 2011 | 1 | 0.020 |
Why?
|
| Glutathione Synthase | 1 | 2011 | 2 | 0.020 |
Why?
|
| Glutathione Reductase | 1 | 2011 | 5 | 0.020 |
Why?
|
| Diet | 1 | 2015 | 497 | 0.020 |
Why?
|
| Malondialdehyde | 1 | 2011 | 13 | 0.020 |
Why?
|
| Heparin | 1 | 1992 | 111 | 0.020 |
Why?
|
| Lipids | 1 | 2014 | 301 | 0.020 |
Why?
|
| Uncoupling Protein 2 | 1 | 2011 | 4 | 0.020 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2011 | 7 | 0.020 |
Why?
|
| Deoxyguanosine | 1 | 2011 | 17 | 0.020 |
Why?
|
| Nasopharynx | 1 | 2011 | 20 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2011 | 27 | 0.020 |
Why?
|
| Amyloid beta-Peptides | 1 | 2013 | 287 | 0.020 |
Why?
|
| Blood Gas Analysis | 1 | 2011 | 34 | 0.020 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 1992 | 105 | 0.020 |
Why?
|
| Glutathione | 1 | 2011 | 54 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 411 | 0.020 |
Why?
|
| Caspase 1 | 1 | 2012 | 107 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2014 | 743 | 0.020 |
Why?
|
| Monitoring, Ambulatory | 1 | 2012 | 56 | 0.020 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2011 | 29 | 0.020 |
Why?
|
| Leukotriene E4 | 1 | 2011 | 7 | 0.020 |
Why?
|
| Leukotriene B4 | 1 | 2011 | 13 | 0.020 |
Why?
|
| Neck Muscles | 1 | 1991 | 10 | 0.020 |
Why?
|
| Ribonuclease III | 1 | 2011 | 82 | 0.020 |
Why?
|
| Esophagus | 1 | 1991 | 50 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2011 | 146 | 0.020 |
Why?
|
| Pressure | 1 | 1991 | 76 | 0.020 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2010 | 7 | 0.020 |
Why?
|
| Suture Techniques | 2 | 1986 | 92 | 0.020 |
Why?
|
| Electromyography | 1 | 1991 | 88 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2012 | 260 | 0.020 |
Why?
|
| Weight Loss | 1 | 2013 | 263 | 0.020 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2011 | 79 | 0.020 |
Why?
|
| Stomach | 1 | 1991 | 83 | 0.020 |
Why?
|
| Plethysmography | 1 | 1990 | 11 | 0.020 |
Why?
|
| Heart | 1 | 2013 | 274 | 0.020 |
Why?
|
| TRPP Cation Channels | 1 | 2010 | 25 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2008 | 51 | 0.020 |
Why?
|
| Pulmonary Circulation | 2 | 2001 | 27 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 47 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 128 | 0.020 |
Why?
|
| Insulin | 1 | 1994 | 673 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2011 | 213 | 0.020 |
Why?
|
| Argonaute Proteins | 1 | 2011 | 129 | 0.020 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2010 | 25 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 145 | 0.020 |
Why?
|
| Zebrafish | 1 | 2013 | 326 | 0.020 |
Why?
|
| Bortezomib | 1 | 2010 | 56 | 0.020 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2012 | 250 | 0.020 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2010 | 64 | 0.020 |
Why?
|
| Complement C4b | 1 | 2009 | 12 | 0.020 |
Why?
|
| Diuretics | 1 | 2010 | 59 | 0.020 |
Why?
|
| Smad3 Protein | 1 | 2009 | 17 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2010 | 117 | 0.020 |
Why?
|
| Swine | 1 | 2010 | 355 | 0.020 |
Why?
|
| Polypharmacy | 1 | 2010 | 61 | 0.020 |
Why?
|
| Colombia | 3 | 1993 | 17 | 0.020 |
Why?
|
| Exons | 1 | 2010 | 191 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2010 | 111 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2009 | 39 | 0.020 |
Why?
|
| Viral Load | 1 | 2010 | 220 | 0.020 |
Why?
|
| Saccharopolyspora | 1 | 2009 | 1 | 0.020 |
Why?
|
| Thyroid Hormones | 1 | 1989 | 74 | 0.020 |
Why?
|
| T-Lymphocytes | 2 | 2009 | 986 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 142 | 0.020 |
Why?
|
| Mice, Inbred DBA | 1 | 2009 | 84 | 0.020 |
Why?
|
| Thoracoscopy | 1 | 2009 | 23 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2012 | 608 | 0.020 |
Why?
|
| Sulfides | 1 | 2008 | 23 | 0.020 |
Why?
|
| Acetates | 1 | 2008 | 33 | 0.020 |
Why?
|
| Stem Cells | 1 | 2010 | 255 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 448 | 0.020 |
Why?
|
| Sperm Count | 1 | 2008 | 15 | 0.020 |
Why?
|
| Rest | 1 | 2008 | 44 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2009 | 95 | 0.020 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2009 | 54 | 0.020 |
Why?
|
| Cysts | 1 | 2008 | 40 | 0.020 |
Why?
|
| Pregnancy Rate | 1 | 2008 | 29 | 0.020 |
Why?
|
| Sperm Motility | 1 | 2008 | 47 | 0.020 |
Why?
|
| Peritonitis | 1 | 2008 | 35 | 0.020 |
Why?
|
| Spermatogenesis | 1 | 2008 | 66 | 0.020 |
Why?
|
| Ovalbumin | 1 | 2008 | 116 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 2009 | 200 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 89 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2007 | 39 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2008 | 226 | 0.020 |
Why?
|
| Hydroxyproline | 1 | 2007 | 5 | 0.020 |
Why?
|
| Connective Tissue Cells | 1 | 2007 | 2 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2007 | 29 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2008 | 450 | 0.020 |
Why?
|
| Reticulocyte Count | 1 | 2007 | 1 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2007 | 32 | 0.020 |
Why?
|
| Haemophilus parainfluenzae | 1 | 2007 | 2 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2008 | 243 | 0.020 |
Why?
|
| Vaginitis | 1 | 2007 | 6 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2007 | 33 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 155 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2007 | 142 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2007 | 74 | 0.020 |
Why?
|
| Alzheimer Disease | 1 | 2013 | 681 | 0.020 |
Why?
|
| Waiting Lists | 1 | 2006 | 48 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase RIIalpha Subunit | 1 | 2006 | 1 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase RIIbeta Subunit | 1 | 2006 | 1 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase RIalpha Subunit | 1 | 2006 | 2 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2007 | 184 | 0.020 |
Why?
|
| Transplantation, Isogeneic | 1 | 2006 | 8 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2007 | 152 | 0.020 |
Why?
|
| Menstrual Cycle | 1 | 1987 | 81 | 0.020 |
Why?
|
| Thyrotropin | 1 | 2006 | 34 | 0.020 |
Why?
|
| Influenza Vaccines | 1 | 2007 | 91 | 0.020 |
Why?
|
| Fertilization in Vitro | 1 | 1987 | 83 | 0.020 |
Why?
|
| Hygiene | 1 | 2006 | 11 | 0.020 |
Why?
|
| Pulmonary Surfactant-Associated Protein B | 1 | 2006 | 1 | 0.020 |
Why?
|
| Latent TGF-beta Binding Proteins | 1 | 2006 | 1 | 0.020 |
Why?
|
| Antidepressive Agents | 1 | 2007 | 212 | 0.020 |
Why?
|
| Chemokine CCL19 | 1 | 2006 | 2 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2007 | 146 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2006 | 17 | 0.020 |
Why?
|
| Leg | 2 | 1999 | 85 | 0.020 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 29 | 0.020 |
Why?
|
| Leukocyte Common Antigens | 1 | 2006 | 58 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2006 | 34 | 0.020 |
Why?
|
| Pulse | 2 | 2003 | 15 | 0.020 |
Why?
|
| Myocardial Contraction | 1 | 1986 | 85 | 0.020 |
Why?
|
| Metrorrhagia | 1 | 2005 | 3 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2006 | 359 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2005 | 31 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2005 | 54 | 0.020 |
Why?
|
| Contraceptive Agents | 1 | 2005 | 12 | 0.020 |
Why?
|
| Mucociliary Clearance | 1 | 2005 | 6 | 0.020 |
Why?
|
| Collagenases | 1 | 2005 | 14 | 0.020 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2005 | 13 | 0.010 |
Why?
|
| Muscle Cells | 1 | 2005 | 26 | 0.010 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2005 | 14 | 0.010 |
Why?
|
| Insurance Coverage | 1 | 2005 | 99 | 0.010 |
Why?
|
| Chromosomes, Human, 6-12 and X | 1 | 1984 | 1 | 0.010 |
Why?
|
| Cell Movement | 1 | 2007 | 428 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2005 | 95 | 0.010 |
Why?
|
| src-Family Kinases | 1 | 2005 | 60 | 0.010 |
Why?
|
| Relaxin | 1 | 2004 | 2 | 0.010 |
Why?
|
| Molybdenum | 1 | 2004 | 4 | 0.010 |
Why?
|
| Endothelin-1 | 1 | 2004 | 7 | 0.010 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2004 | 6 | 0.010 |
Why?
|
| Nucleoside Deaminases | 1 | 1984 | 3 | 0.010 |
Why?
|
| Chemokine CCL7 | 1 | 2004 | 1 | 0.010 |
Why?
|
| Renin-Angiotensin System | 1 | 2004 | 21 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 1984 | 62 | 0.010 |
Why?
|
| Adenosine Deaminase | 1 | 1984 | 17 | 0.010 |
Why?
|
| Eicosanoids | 1 | 2004 | 25 | 0.010 |
Why?
|
| Abnormalities, Multiple | 1 | 1984 | 51 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2007 | 378 | 0.010 |
Why?
|
| Immediate-Early Proteins | 1 | 2004 | 44 | 0.010 |
Why?
|
| Liver, Artificial | 1 | 2003 | 2 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2009 | 605 | 0.010 |
Why?
|
| Constriction, Pathologic | 2 | 1995 | 112 | 0.010 |
Why?
|
| Valsartan | 1 | 2003 | 12 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 188 | 0.010 |
Why?
|
| DNA Primers | 1 | 2004 | 289 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2004 | 165 | 0.010 |
Why?
|
| Antigens, Protozoan | 2 | 1994 | 43 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 152 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 318 | 0.010 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2003 | 64 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 841 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2007 | 1997 | 0.010 |
Why?
|
| Functional Residual Capacity | 2 | 1993 | 4 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 2 | 1997 | 25 | 0.010 |
Why?
|
| Liver Diseases | 1 | 2003 | 137 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2006 | 1368 | 0.010 |
Why?
|
| Jugular Veins | 2 | 2000 | 29 | 0.010 |
Why?
|
| Israel | 1 | 2001 | 17 | 0.010 |
Why?
|
| Hospitals, Special | 1 | 2001 | 9 | 0.010 |
Why?
|
| Cross-Cultural Comparison | 1 | 2001 | 43 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2005 | 552 | 0.010 |
Why?
|
| Heart Transplantation | 1 | 2003 | 162 | 0.010 |
Why?
|
| Epoprostenol | 1 | 2001 | 14 | 0.010 |
Why?
|
| Histamine | 1 | 1981 | 26 | 0.010 |
Why?
|
| Aldosterone | 1 | 2001 | 17 | 0.010 |
Why?
|
| Lactams | 1 | 2000 | 18 | 0.010 |
Why?
|
| Sample Size | 1 | 2001 | 61 | 0.010 |
Why?
|
| Systole | 1 | 2001 | 109 | 0.010 |
Why?
|
| Cannabis | 1 | 1981 | 51 | 0.010 |
Why?
|
| Ventricular Function | 1 | 1999 | 22 | 0.010 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 1999 | 2 | 0.010 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 1999 | 11 | 0.010 |
Why?
|
| Radiography, Interventional | 1 | 2000 | 72 | 0.010 |
Why?
|
| Aerosols | 1 | 1999 | 40 | 0.010 |
Why?
|
| Antitubercular Agents | 1 | 2000 | 76 | 0.010 |
Why?
|
| New Mexico | 1 | 1998 | 9 | 0.010 |
Why?
|
| Planning Techniques | 1 | 1998 | 14 | 0.010 |
Why?
|
| Cost Control | 1 | 1998 | 24 | 0.010 |
Why?
|
| Hypotension | 1 | 1998 | 48 | 0.010 |
Why?
|
| Software Design | 1 | 1998 | 27 | 0.010 |
Why?
|
| South America | 1 | 1997 | 23 | 0.010 |
Why?
|
| Asia | 1 | 1997 | 18 | 0.010 |
Why?
|
| Liver | 1 | 2002 | 796 | 0.010 |
Why?
|
| Yemen | 1 | 1997 | 1 | 0.010 |
Why?
|
| Kidney Glomerulus | 1 | 1997 | 21 | 0.010 |
Why?
|
| Breathing Exercises | 1 | 1997 | 5 | 0.010 |
Why?
|
| Carcinoma, Large Cell | 1 | 1997 | 5 | 0.010 |
Why?
|
| Travel | 1 | 1997 | 37 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 1997 | 10 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1997 | 14 | 0.010 |
Why?
|
| Resuscitation | 1 | 1977 | 70 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 1997 | 81 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2004 | 733 | 0.010 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 1996 | 19 | 0.010 |
Why?
|
| Hospitals, Veterans | 1 | 1998 | 159 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 1996 | 76 | 0.010 |
Why?
|
| Health Care Costs | 1 | 1998 | 202 | 0.010 |
Why?
|
| Intestine, Small | 1 | 1996 | 77 | 0.010 |
Why?
|
| Program Evaluation | 1 | 1998 | 470 | 0.010 |
Why?
|
| Heart Arrest | 1 | 1977 | 161 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 1995 | 27 | 0.010 |
Why?
|
| Emergency Medicine | 1 | 1977 | 182 | 0.010 |
Why?
|
| Quality Indicators, Health Care | 1 | 1998 | 333 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1995 | 214 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1997 | 237 | 0.010 |
Why?
|
| Hungary | 1 | 1994 | 3 | 0.010 |
Why?
|
| Erythrocyte Indices | 1 | 1994 | 5 | 0.010 |
Why?
|
| Tricuspid Valve | 1 | 1975 | 20 | 0.010 |
Why?
|
| Thiorphan | 1 | 1994 | 1 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 1996 | 227 | 0.010 |
Why?
|
| Renal Circulation | 1 | 1994 | 11 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1994 | 25 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 1995 | 107 | 0.010 |
Why?
|
| Protein Denaturation | 1 | 1994 | 67 | 0.010 |
Why?
|
| Electrolytes | 1 | 1994 | 25 | 0.010 |
Why?
|
| Tanzania | 1 | 1994 | 19 | 0.010 |
Why?
|
| Dextrans | 1 | 1994 | 45 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1994 | 102 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1997 | 323 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1994 | 184 | 0.010 |
Why?
|
| Viral Vaccines | 1 | 1994 | 47 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1996 | 550 | 0.010 |
Why?
|
| Data Collection | 1 | 1995 | 372 | 0.010 |
Why?
|
| Agriculture | 1 | 1993 | 30 | 0.010 |
Why?
|
| Physical Education and Training | 1 | 1993 | 29 | 0.010 |
Why?
|
| Edema | 1 | 1993 | 42 | 0.010 |
Why?
|
| Foot | 1 | 1993 | 41 | 0.010 |
Why?
|
| Risk-Taking | 1 | 1993 | 158 | 0.010 |
Why?
|
| Hand | 1 | 1993 | 69 | 0.010 |
Why?
|
| Skin | 1 | 1993 | 357 | 0.010 |
Why?
|
| Urinary Bladder | 1 | 1970 | 38 | 0.010 |
Why?
|
| Biological Transport | 1 | 1970 | 288 | 0.000 |
Why?
|
| Superovulation | 1 | 1987 | 3 | 0.000 |
Why?
|
| Follicular Phase | 1 | 1987 | 15 | 0.000 |
Why?
|
| Luteal Phase | 1 | 1987 | 28 | 0.000 |
Why?
|
| Prolactin | 1 | 1987 | 40 | 0.000 |
Why?
|
| Inhibins | 1 | 1987 | 50 | 0.000 |
Why?
|
| Luteinizing Hormone | 1 | 1987 | 98 | 0.000 |
Why?
|
| Ovary | 1 | 1987 | 98 | 0.000 |
Why?
|
| Estradiol | 1 | 1987 | 247 | 0.000 |
Why?
|
| Oocytes | 1 | 1987 | 193 | 0.000 |
Why?
|
| Chromosome Banding | 1 | 1984 | 10 | 0.000 |
Why?
|
| Karyotyping | 1 | 1984 | 44 | 0.000 |
Why?
|
| Chromosome Disorders | 1 | 1984 | 14 | 0.000 |
Why?
|
| Stem Cell Transplantation | 1 | 1985 | 75 | 0.000 |
Why?
|
| Herpes Simplex | 1 | 1985 | 48 | 0.000 |
Why?
|
| Tachycardia | 1 | 1984 | 28 | 0.000 |
Why?
|
| Pulmonary Edema | 1 | 1984 | 28 | 0.000 |
Why?
|
| Recombination, Genetic | 1 | 1984 | 238 | 0.000 |
Why?
|
| Reoperation | 1 | 1984 | 272 | 0.000 |
Why?
|
| Bronchospirometry | 1 | 1981 | 1 | 0.000 |
Why?
|
| Administration, Intranasal | 1 | 1981 | 28 | 0.000 |
Why?
|
| Withholding Treatment | 1 | 1977 | 40 | 0.000 |
Why?
|
| Apnea | 1 | 1977 | 30 | 0.000 |
Why?
|
| Emergencies | 1 | 1977 | 110 | 0.000 |
Why?
|
| Calcinosis | 1 | 1975 | 79 | 0.000 |
Why?
|
| Diuresis | 1 | 1970 | 5 | 0.000 |
Why?
|
| Femoral Vein | 1 | 1970 | 18 | 0.000 |
Why?
|
| Ultracentrifugation | 1 | 1970 | 28 | 0.000 |
Why?
|